<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Interventions for preventing high altitude illness: Part 2. Less commonly‐used drugs - Gonzalez Garay, AG - 2018 | Cochrane Library</title> <meta content="Interventions for preventing high altitude illness: Part 2. Less commonly‐used drugs - Gonzalez Garay, AG - 2018 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012983/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Interventions for preventing high altitude illness: Part 2. Less commonly‐used drugs - Gonzalez Garay, AG - 2018 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012983/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD012983" name="dc.identifier" scheme="DOI"/> <meta content="Interventions for preventing high altitude illness: Part 2. Less commonly‐used drugs" name="citation_title"/> <meta content="Alejandro G Gonzalez Garay" name="citation_author"/> <meta content="National Institute of Pediatrics" name="citation_author_institution"/> <meta content="Daniel Molano Franco" name="citation_author"/> <meta content="Fundacion Universitaria de Ciencias de la Salud, Hospital de San José" name="citation_author_institution"/> <meta content="Víctor H Nieto Estrada" name="citation_author"/> <meta content="Fundacion Universitaria Sanitas, Colombia Clinic" name="citation_author_institution"/> <meta content="Arturo J Martí‐Carvajal" name="citation_author"/> <meta content="Iberoamerican Cochrane Network" name="citation_author_institution"/> <meta content="Ingrid Arevalo‐Rodriguez" name="citation_author"/> <meta content="inarev7@yahoo.com" name="citation_author_email"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="3" name="citation_issue"/> <meta content="10.1002/14651858.CD012983" name="citation_doi"/> <meta content="2018" name="citation_date"/> <meta content="2018/03/12" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012983/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012983/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012983/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Acetazolamide [*therapeutic use]; Altitude Sickness [*prevention &amp; control]; Cathartics [adverse effects, *therapeutic use]; Citric Acid [adverse effects, *therapeutic use]; Diuretics [*therapeutic use]; Organometallic Compounds [adverse effects, *therapeutic use]; Randomized Controlled Trials as Topic; Spironolactone [*therapeutic use]; Sumatriptan [*therapeutic use]" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012983&amp;doi=10.1002/14651858.CD012983&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012983&amp;doi=10.1002/14651858.CD012983&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012983&amp;doi=10.1002/14651858.CD012983&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012983&amp;doi=10.1002/14651858.CD012983&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012983&amp;doi=10.1002/14651858.CD012983&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012983&amp;doi=10.1002/14651858.CD012983&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012983&amp;doi=10.1002/14651858.CD012983&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012983&amp;doi=10.1002/14651858.CD012983&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012983&amp;doi=10.1002/14651858.CD012983&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012983&amp;doi=10.1002/14651858.CD012983&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012983&amp;doi=10.1002/14651858.CD012983&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012983&amp;doi=10.1002/14651858.CD012983&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012983&amp;doi=10.1002/14651858.CD012983&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012983&amp;doi=10.1002/14651858.CD012983&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012983&amp;doi=10.1002/14651858.CD012983&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012983&amp;doi=10.1002/14651858.CD012983&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012983&amp;doi=10.1002/14651858.CD012983&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012983&amp;doi=10.1002/14651858.CD012983&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012983&amp;doi=10.1002/14651858.CD012983&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012983&amp;doi=10.1002/14651858.CD012983&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012983&amp;doi=10.1002/14651858.CD012983&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012983&amp;doi=10.1002/14651858.CD012983&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012983&amp;doi=10.1002/14651858.CD012983&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772874000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772901000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000"}};Liferay.authToken="PrHmaMrX";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD012983\x26doi\x3d10\x2e1002\x2f14651858\x2eCD012983\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012983\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012983\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513679709000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","zh_HANT","ms","fa"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD012983",title:"Interventions for preventing high altitude illness: Part 2. Less commonly\\u2010used drugs",firstPublishedDate:"Mar 12, 2018 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Emergency and Critical Care Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734064000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=PrHmaMrX&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD012983&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD012983';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD012983/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD012983/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD012983%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD012983/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD012983/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD012983/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD012983/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD012983" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;zh_HANT&quot;,&quot;title&quot;:&quot;Plain language summary&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD012983/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD012983" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD012983/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD012983/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>2853 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD012983" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012983/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012983/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012983/full#CD012983-abs-0003"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012983/full#CD012983-sec-0106"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012983/full#CD012983-sec-0015"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012983/full#CD012983-sec-0016"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012983/full#CD012983-sec-0025"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012983/full#CD012983-sec-0026"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012983/full#CD012983-sec-0050"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012983/full#CD012983-sec-0096"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD012983/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012983/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012983/appendices#CD012983-sec-0111"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012983/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012983/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD012983/media/CDSR/CD012983/table_n/CD012983StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD012983/media/CDSR/CD012983/table_n/CD012983StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012983/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012983/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012983/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD012983/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD012983/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD012983/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2018 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD012983/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Interventions for preventing high altitude illness: Part 2. Less commonly‐used drugs</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012983/information#CD012983-cr-0002">Alejandro G Gonzalez Garay</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012983/information#CD012983-cr-0003">Daniel Molano Franco</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012983/information#CD012983-cr-0004">Víctor H Nieto Estrada</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012983/information#CD012983-cr-0005">Arturo J Martí‐Carvajal</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012983/information#CD012983-cr-0006"><i class="icon corresponding-author fa fa-envelope"></i>Ingrid Arevalo‐Rodriguez</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD012983/information/en#CD012983-sec-0136">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 12 March 2018 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD012983/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD012983">https://doi.org/10.1002/14651858.CD012983</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD012983-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD012983-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD012983-abs-0002">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD012983-abs-0007">فارسی</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD012983-abs-0001" lang="en"> <section id="CD012983-sec-0001"> <h3 class="title" id="CD012983-sec-0001">Background</h3> <p>High altitude illness (HAI) is a term used to describe a group of mainly cerebral and pulmonary syndromes that can occur during travel to elevations above 2500 metres (˜ 8200 feet). Acute mountain sickness (AMS), high altitude cerebral oedema (HACE) and high altitude pulmonary oedema (HAPE) are reported as potential medical problems associated with high altitude ascent. In this second review, in a series of three about preventive strategies for HAI, we assessed the effectiveness of five of the less commonly used classes of pharmacological interventions. </p> </section> <section id="CD012983-sec-0002"> <h3 class="title" id="CD012983-sec-0002">Objectives</h3> <p>To assess the clinical effectiveness and adverse events of five of the less commonly used pharmacological interventions for preventing acute HAI in participants who are at risk of developing high altitude illness in any setting. </p> </section> <section id="CD012983-sec-0003"> <h3 class="title" id="CD012983-sec-0003">Search methods</h3> <p>We searched the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, Embase, LILACS and the World Health Organization International Clinical Trials Registry Platform (WHO ICTRP) in May 2017. We adapted the MEDLINE strategy for searching the other databases. We used a combination of thesaurus‐based and free‐text search terms. We scanned the reference lists and citations of included trials and any relevant systematic reviews that we identified for further references to additional trials. </p> </section> <section id="CD012983-sec-0004"> <h3 class="title" id="CD012983-sec-0004">Selection criteria</h3> <p>We included randomized controlled trials conducted in any setting where one of five classes of drugs was employed to prevent acute HAI: selective 5‐hydroxytryptamine(1) receptor agonists; N‐methyl‐D‐aspartate (NMDA) antagonist; endothelin‐1 antagonist; anticonvulsant drugs; and spironolactone. We included trials involving participants who are at risk of developing high altitude illness (AMS or HACE, or HAPE, or both). We included participants with and without a history of high altitude illness. We applied no age or gender restrictions. We included trials where the relevant medication was administered before the beginning of ascent. We excluded trials using these drugs during ascent or after ascent. </p> </section> <section id="CD012983-sec-0005"> <h3 class="title" id="CD012983-sec-0005">Data collection and analysis</h3> <p>We used the standard methodological procedures employed by Cochrane.</p> </section> <section id="CD012983-sec-0006"> <h3 class="title" id="CD012983-sec-0006">Main results</h3> <p>We included eight studies (334 participants, 9 references) in this review. Twelve studies are ongoing and will be considered in future versions of this review as appropriate. We have been unable to obtain full‐text versions of a further 12 studies and have designated them as 'awaiting classification'. Four studies were at a low risk of bias for randomization; two at a low risk of bias for allocation concealment. Four studies were at a low risk of bias for blinding of participants and personnel. We considered three studies at a low risk of bias for blinding of outcome assessors. We considered most studies at a high risk of selective reporting bias. </p> <p>We report results for the following four main comparisons.</p> <p><b>Sumatriptan versus placebo (1 parallel study; 102 participants)</b> </p> <p>Data on sumatriptan showed a reduction of the risk of AMS when compared with a placebo (risk ratio (RR) = 0.43, CI 95% 0.21 to 0.84; 1 study, 102 participants; low quality of evidence). The one included study did not report events of HAPE, HACE or adverse events related to administrations of sumatriptan. </p> <p><b>Magnesium citrate versus placebo (1 parallel study; 70 participants)</b> </p> <p>The estimated RR for AMS, comparing magnesium citrate tablets versus placebo, was 1.09 (95% CI 0.55 to 2.13; 1 study; 70 participants; low quality of evidence). In addition, the estimated RR for loose stools was 3.25 (95% CI 1.17 to 8.99; 1 study; 70 participants; low quality of evidence). The one included study did not report events of HAPE or HACE. </p> <p><b>Spironolactone versus placebo (2 parallel studies; 205 participants)</b> </p> <p>Pooled estimation of RR for AMS was not performed due to considerable heterogeneity between the included studies (I² = 72%). RR from individual studies was 0.40 (95% CI 0.12 to 1.31) and 1.44 (95% CI 0.79 to 2.01; very low quality of evidence). No events of HAPE or HACE were reported. Adverse events were not evaluated. </p> <p><b>Acetazolamide versus spironolactone (1 parallel study; 232 participants)</b> </p> <p>Data on acetazolamide compared with spironolactone showed a reduction of the risk of AMS with the administration of acetazolamide (RR = 0.36, 95% CI 0.18 to 0.70; 232 participants; low quality of evidence). No events of HAPE or HACE were reported. Adverse events were not evaluated. </p> </section> <section id="CD012983-sec-0007"> <h3 class="title" id="CD012983-sec-0007">Authors' conclusions</h3> <p>This Cochrane Review is the second in a series of three providing relevant information to clinicians and other interested parties on how to prevent high altitude illness. The assessment of five of the less commonly used classes of drugs suggests that there is a scarcity of evidence related to these interventions. Clinical benefits and harms related to potential interventions such as sumatriptan are still unclear. Overall, the evidence is limited due to the low number of studies identified (for most of the comparison only one study was identified); limitations in the quality of the evidence (moderate to low); and the number of studies pending classification (24 studies awaiting classification or ongoing). We lack the large and methodologically sound studies required to establish or refute the efficacy and safety of most of the pharmacological agents evaluated in this review. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD012983-abs-0003" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD012983-abs-0003">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD012983-abs-0006">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD012983-abs-0008">فارسی</a> </li> <li class="section-language"> <a class="" href="full/ms#CD012983-abs-0005">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/zh_HANT#CD012983-abs-0004">繁體中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD012983-abs-0003" lang="en"> <h3>Medicines less commonly used for preventing high altitude illness</h3> <p><b>Background</b> </p> <p>High altitude illness (HAI) is a term used to describe a group of brain and lung conditions that can occur during travel to altitudes above 2500 metres (˜ 8200 feet). HAI‐related conditions are generally characterized by headache, nausea, vomiting and tiredness (often called acute mountain sickness), but primarily affect the brain (drowsiness, confusion or unconsciousness) or the lungs (cough, breathlessness) in different individuals. We assessed five classes of medicines less commonly used to prevent the onset of this illness in this review. </p> <p><b>Study characteristics</b> </p> <p>The evidence is current to May 2017. We included eight studies and 334 participants related to five different classes of medicines sometimes recommended for HAI prevention. These medicines included those that mimic the action of serotonin at selected sites (selective 5‐hydroxytryptamine(1) receptor agonists), medicines that regulate the action of calcium (N‐methyl‐D‐aspartate (NMDA) antagonist), medicines that promote dilation of the blood vessels (endothelin‐1 antagonist), medicines that prevent a neuron (nerve cell) from 'firing' (initiating an action) and convulsions from developing (anticonvulsant medicines), as well as medicines that regulate the body´s sodium and water levels (spironolactone). All studies were undertaken in high altitude mountain areas. The participants ranged between 16 and 65 years of age. Only one study included people at a high risk of this condition due to their history of HAI. Four trials provided the intervention between one to three days prior to the ascent (50%), and three trials less than 24 hours prior (37.5%). The participants in all these studies reached a final altitude of between 3500 and 5895 metres above sea level. Only one of the eight included studies did not provide clear information about the source of funding (12.5%). Twenty‐four additional studies were classified as ongoing (12), or awaiting classification (12; unable to obtain full texts). </p> <p><b>Key results</b> </p> <p>The assessment of the less commonly used pharmacological interventions suggest that there is a scarcity of evidence related to these interventions. For most of the assessed comparisons, we only found evidence from a single study. Clinical benefits and harms related to potential interventions such as sumatriptan are still unclear. </p> <p><b>Quality of the evidence</b> </p> <p>The quality of the evidence was rated from low to very low. Several studies had quality shortcomings such as only having small sample sizes and therefore generating uncertain results. For most of the medicines evaluated, additional research is required to clarify their effectiveness and safety. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD012983-sec-0106" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD012983-sec-0106"></div> <h3 class="title" id="CD012983-sec-0107">Implications for practice</h3> <section id="CD012983-sec-0107"> <p>The assessment of five of the less commonly used classes of drugs suggests there is little evidence available concerning these interventions in prevention of HAI conditions. Clinical benefits and harms related to these potential interventions remain unclear. Overall, the evidence is of limited practical significance in the clinical field. </p> </section> <h3 class="title" id="CD012983-sec-0108">Implications for research</h3> <section id="CD012983-sec-0108"> <p>There is a lack of large and multi‐centre studies of most of the pharmacological agents evaluated in this review. For most of the comparisons evaluated, small sample sizes and lack of reporting of adverse events affect the quality of results. Further studies should also evaluate combinations of pharmacological strategies to prevent HAI. Design of future trials might be improved by the following suggestions. </p> <p> <ol id="CD012983-list-0010"> <li> <p>Refining the operative definition of HAI conditions by selecting a unified scale and threshold. </p> </li> <li> <p>Improving the reporting of statistical data related to important outcomes in order to avoid missing data, and inclusion of information about elevation where HAI occurs. </p> </li> <li> <p>Adding adverse events as an important endpoint in assessment of these preventive strategies.</p> </li> <li> <p>Comparing potential pharmacological agents against interventions of well‐known effectiveness (such as acetazolamide, an intervention assessed in the first part of this series of reviews). </p> </li> </ol> </p> <p>Finally, we suggest performing a network meta‐analysis of all interventions (pharmacological and non‐pharmacological) used for high altitude illness prevention, in order to determine which interventions are more effective in avoiding the onset of new cases of this condition. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD012983-sec-0015" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD012983-sec-0015"></div> <div class="table" id="CD012983-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Sumatriptan compared with placebo for preventing high altitude illness</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Sumatriptan compared with placebo for preventing high altitude illness</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> participants at risk of high altitude illness<br/> <b>Setting:</b> High altitude (Ecuador) </p> <p><b>Intervention:</b> sumatriptan<br/> <b>Comparison:</b> placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Placebo</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Sumatriptan</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Risk of acute mountain sickness</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>412 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>177 per 1000</b><br/> (91 to 346) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.43</b> <br/> (0.21 to 0.84) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>102<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low</b><sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Risk of high altitude pulmonary oedema</b> ‐ not reported </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>Not estimable</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Risk of high altitude cerebral oedema</b> ‐ not reported </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>Not estimable</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Risk of adverse events</b> ‐ not reported </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>Not estimable</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Downgraded 2 levels due to imprecision. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD012983-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Magnesium citrate compared with placebo for preventing high altitude illness</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Magnesium citrate compared with placebo for preventing high altitude illness</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> participants at risk of high altitude illness<br/> <b>Setting:</b> High altitude (Italy) </p> <p><b>Intervention:</b> magnesium citrate<br/> <b>Comparison:</b> placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>placebo</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Magnesium</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Risk of acute mountain sickness</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>314 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>343 per 1000</b><br/> (176 to 669) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.09</b> <br/> (0.55 to 2.13) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>70<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low</b><sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Risk of high altitude pulmonary oedema</b>‐ not reported </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>Not estimable</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Risk of high altitude cerebral oedema</b>‐ not reported </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>Not estimable</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Risk of adverse events: Loose stools</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>114 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>371 per 1000</b><br/> (134 to 1000) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 3.25</b> <br/> (1.17 to 8.99) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>70<br/> (1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊝⊝<br/> <b>Low</b><sup>1</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Imprecision downgraded by 2 levels due to insufficient sample size to determine whether there are differences or no differences between these 2 groups. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD012983-tbl-0003"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Spironolactone compared with placebo for preventing high altitude illness</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Spironolactone compared with placebo for preventing high altitude illness</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> participants at risk of high altitude illness<br/> <b>Setting:</b> High altitude (Tanzania) </p> <p><b>Intervention:</b> spironolactone<br/> <b>Comparison:</b> placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Placebo</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Spironolactone</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Risk of acute mountain sickness</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>205<br/> (2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low</b><sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR ranged from 0.40 to 1.44</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Risk of high altitude pulmonary oedema</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>Not estimable</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>193<br/> (1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No HAPE events recorded</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Risk of</b> High altitude<b>cerebral oedema</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>Not estimable</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>193<br/> (1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No HACE events recorded</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Risk of adverse events</b> ‐ not reported </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>Not estimable</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Quality of evidence downgraded from high to very low due to a high risk of bias, imprecision and inconsistency. </p> <p>2 Quality of evidence downgraded from high to low due to unclear risk of selection, performance and detection bias, as well as imprecision issues </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD012983-tbl-0004"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Acetazolamide compared with spironolactone for preventing high altitude illness</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Acetazolamide compared with spironolactone for preventing high altitude illness</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population</b> : participants at risk of high altitude illness<br/> <b>Setting</b>: High altitude (Nepal) </p> <p><b>Intervention</b> : spironolactone<br/> <b>Comparison</b>: placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Spironolactone</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Acetazolamide</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Risk of acute mountain sickness</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>237 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>85 per 1000</b><br/> (43 to 168) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.36</b> <br/> (0.18 to 0.70) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>232<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Risk of high altitude pulmonary oedema</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>232<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No HAPE events recorded</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Risk of high altitude cerebral oedema</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>232<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No HACE events recorded</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Risk of adverse events</b> ‐ not reported </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio; </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Risk of bias downgraded by 1 level due to unclear selection, performance and detection bias.<br/> <sup>2</sup> Imprecision downgraded by 1 level due to insufficient sample size to determine whether there are differences or no between these 2 groups. </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD012983-sec-0016" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD012983-sec-0016"></div> <p>High altitude illness (HAI) is a term used to describe a group of cerebral and pulmonary syndromes that can occur during travel to elevations above 2500 metres (m) (˜ 8200 feet). HAI is commonly classified as high (1500 m to 3500 m), very high (above 3500 m to 5500 m) and extreme (above 5500 m) (<a href="./references#CD012983-bbs2-0090" title="FlahertyGT , KennedyKM . Preparing patients for travel to high altitude: advice on travel health and chemoprophylaxis. British Journal of General Practice : the Journal of the Royal College of General Practitioners2016;66(642):e62‐4. [PUBMED: 26719484] ">Flaherty 2016</a>; <a href="./references#CD012983-bbs2-0111" title="KayserB , DumontL , LysakowskiC , CombescureC , HallerG , TramerMR . Reappraisal of acetazolamide for the prevention of acute mountain sickness: a systematic review and meta‐analysis. High Altitude Medicine &amp; Biology2012;13(2):82‐92. [PUBMED: 22724610] ">Kayser 2012</a>; <a href="./references#CD012983-bbs2-0112" title="KhodaeeM , GrotheHL , SeyfertJH , VanBaakK . Athletes at high altitude. Sports Health2016;8(2):126‐32. [PUBMED: 26863894] ">Khodaee 2016</a>; <a href="./references#CD012983-bbs2-0115" title="LowEV , AveryAJ , GuptaV , SchedlbauerA , GrocottMP . Identifying the lowest effective dose of acetazolamide for the prophylaxis of acute mountain sickness: systematic review and meta‐analysis. BMJ (Clinical research ed.)2012;345:e6779. [PUBMED: 23081689] ">Low 2012</a>; <a href="./references#CD012983-bbs2-0133" title="ParalikarSJ , ParalikarJH . High‐altitude medicine. Indian Journal of Occupational and Environmental Medicine2010;14(1):6‐12. [PUBMED: 20808661] ">Paralikar 2010</a>; <a href="./references#CD012983-bbs2-0158" title="ZafrenK . Prevention of high altitude illness. Travel Medicine and Infectious Disease2014;12(1):29‐39. [PUBMED: 24393671] ">Zafren 2014</a>). Because of the large number of people who ascend rapidly to between 2500 m and 3500 m, high altitude illness is common in this height range as a result of hypoxia (<a href="./references#CD012983-bbs2-0085" title="DavisC , HackettP . Advances in the Prevention and Treatment of High Altitude Illness. Emergency Medicine Clinics of North America2017;35(2):241‐60. [PUBMED: 28411926] ">Davis 2017</a>; <a href="./references#CD012983-bbs2-0133" title="ParalikarSJ , ParalikarJH . High‐altitude medicine. Indian Journal of Occupational and Environmental Medicine2010;14(1):6‐12. [PUBMED: 20808661] ">Paralikar 2010</a>). Although the proportion of oxygen remains unchanged at 20.93%, increases in altitude result in a lower partial pressure of oxygen in the inspired air (<a href="./references#CD012983-bbs2-0072" title="Anonymous . Mountain sickness. British Medical Journal1892;1(1633):829. [PUBMED: 20753647] ">Anonymous 1892</a>; <a href="./references#CD012983-bbs2-0154" title="WilsonMH , NewmanS , ImrayCH . The cerebral effects of ascent to high altitudes. Lancet Neurology2009;8(2):175‐91. [PUBMED: 19161909] ">Wilson 2009</a>). This reduction in the driving pressure of oxygen along the oxygen cascade from the lungs to the tissues can compromise the supply of oxygen to the tissues (<a href="./references#CD012983-bbs2-0154" title="WilsonMH , NewmanS , ImrayCH . The cerebral effects of ascent to high altitudes. Lancet Neurology2009;8(2):175‐91. [PUBMED: 19161909] ">Wilson 2009</a>), especially the cardiovascular and pulmonary systems (<a href="./references#CD012983-bbs2-0114" title="LeissnerKB , MahmoodFU . Physiology and pathophysiology at high altitude: considerations for the anesthesiologist. Journal of Anesthesia2009;23(4):543‐53. [PUBMED: 19921365 ] ">Leissner 2009</a>). The physiological responses to hypoxia and acclimatization related to HAI include hyperventilation (increased depth and rate of breathing); elevation of systemic blood pressure; and tachycardia (elevations of heart rate) (<a href="./references#CD012983-bbs2-0114" title="LeissnerKB , MahmoodFU . Physiology and pathophysiology at high altitude: considerations for the anesthesiologist. Journal of Anesthesia2009;23(4):543‐53. [PUBMED: 19921365 ] ">Leissner 2009</a>; <a href="./references#CD012983-bbs2-0130" title="NaeijeR . Physiological adaptation of the cardiovascular system to high altitude. Progress in Cardiovascular Diseases2010;52(6):456‐66. [PUBMED: 20417339] ">Naeije 2010</a>). However, in many instances these physiological changes may be inadequate, so that the ascent to high altitude and the attendant hypoxia are complicated by altitude‐associated medical illness (<a href="./references#CD012983-bbs2-0120" title="LuksAM , SwensonER , BartschP . Acute high‐altitude sickness. European Respiratory Review : an Official Journal of the European Respiratory Society2017;26(143):160096. [PUBMED: 28143879] ">Luks 2017</a>; <a href="./references#CD012983-bbs2-0132" title="PalmerBF . Physiology and pathophysiology with ascent to altitude. American Journal of the Medical Sciences2010;340(1):69‐77. [PUBMED: 20442648] ">Palmer 2010</a>), which is also known as high altitude illness (HAI). </p> <section id="CD012983-sec-0017"> <h3 class="title" id="CD012983-sec-0017">Description of the condition</h3> <section id="CD012983-sec-0018"> <h4 class="title">High altitude illness (HAI)</h4> <p>As mentioned earlier, HAI is a term used to describe a group of mainly cerebral and pulmonary syndromes that can occur during travel to elevations above 2500 metres. There are two types of mountain sickness: acute mountain sickness; and chronic mountain sickness (CMS), also called Monge's disease (<a href="./references#CD012983-bbs2-0128" title="MongeC . Life in the Andes and chronic mountain sickness. Science1942;95(2456):79‐84. [PUBMED: 17757318] ">Monge 1942</a>). Acute hypoxia, acute mountain sickness (AMS), high altitude cerebral oedema (HACE), high altitude pulmonary oedema (HAPE), cerebrovascular syndromes, peripheral oedema, retinopathy, thromboembolism, sleep disorders and periodic breathing, high altitude pharyngitis and bronchitis, ultraviolet exposure and keratitis (snow blindness), and exacerbation of pre‐existing illness are reported as potential medical problems associated with high altitude ascent (<a href="./references#CD012983-bbs2-0081" title="Committee to Advise on Tropical Medicine and Travel (CATMAT). Statement on high‐altitude illnesses. An Advisory Committee Statement (ACS). Canada Communicable Disease Report = Relevé des maladies transmissibles au Canada2007;33(ACS‐5):1‐20. [PUBMED: 17520777] ">CATMAT 2007</a>; <a href="./references#CD012983-bbs2-0111" title="KayserB , DumontL , LysakowskiC , CombescureC , HallerG , TramerMR . Reappraisal of acetazolamide for the prevention of acute mountain sickness: a systematic review and meta‐analysis. High Altitude Medicine &amp; Biology2012;13(2):82‐92. [PUBMED: 22724610] ">Kayser 2012</a>; <a href="./references#CD012983-bbs2-0112" title="KhodaeeM , GrotheHL , SeyfertJH , VanBaakK . Athletes at high altitude. Sports Health2016;8(2):126‐32. [PUBMED: 26863894] ">Khodaee 2016</a>; <a href="./references#CD012983-bbs2-0132" title="PalmerBF . Physiology and pathophysiology with ascent to altitude. American Journal of the Medical Sciences2010;340(1):69‐77. [PUBMED: 20442648] ">Palmer 2010</a>; <a href="./references#CD012983-bbs2-0142" title="SchoeneRB . Illnesses at high altitude. Chest2008;134(2):402‐16. [PUBMED: 18682459] ">Schoene 2008</a>). Factors such as the rate of ascent, the absolute change in altitude, and individual physiology are factors usually implicated in the development of these conditions (<a href="./references#CD012983-bbs2-0090" title="FlahertyGT , KennedyKM . Preparing patients for travel to high altitude: advice on travel health and chemoprophylaxis. British Journal of General Practice : the Journal of the Royal College of General Practitioners2016;66(642):e62‐4. [PUBMED: 26719484] ">Flaherty 2016</a>; <a href="./references#CD012983-bbs2-0114" title="LeissnerKB , MahmoodFU . Physiology and pathophysiology at high altitude: considerations for the anesthesiologist. Journal of Anesthesia2009;23(4):543‐53. [PUBMED: 19921365 ] ">Leissner 2009</a>; <a href="./references#CD012983-bbs2-0115" title="LowEV , AveryAJ , GuptaV , SchedlbauerA , GrocottMP . Identifying the lowest effective dose of acetazolamide for the prophylaxis of acute mountain sickness: systematic review and meta‐analysis. BMJ (Clinical research ed.)2012;345:e6779. [PUBMED: 23081689] ">Low 2012</a>; <a href="./references#CD012983-bbs2-0120" title="LuksAM , SwensonER , BartschP . Acute high‐altitude sickness. European Respiratory Review : an Official Journal of the European Respiratory Society2017;26(143):160096. [PUBMED: 28143879] ">Luks 2017</a>; <a href="./references#CD012983-bbs2-0132" title="PalmerBF . Physiology and pathophysiology with ascent to altitude. American Journal of the Medical Sciences2010;340(1):69‐77. [PUBMED: 20442648] ">Palmer 2010</a>; <a href="./references#CD012983-bbs2-0158" title="ZafrenK . Prevention of high altitude illness. Travel Medicine and Infectious Disease2014;12(1):29‐39. [PUBMED: 24393671] ">Zafren 2014</a>). The risk categories for acute mountain sickness are shown in <a href="./appendices#CD012983-sec-0112">Appendix 1</a> (<a href="./references#CD012983-bbs2-0118" title="LuksAM , McIntoshSE , GrissomCK , AuerbachPS , RodwayGW , SchoeneRB , et al. Wilderness Medical Society consensus guidelines for the prevention and treatment of acute altitude illness. Wilderness &amp; Environmental Medicine2010;21(2):146‐55. [PUBMED: 20591379] ">Luks 2010</a>). </p> <p>In the 19th century Dr Daniel Vergara, a Mexican physiologist, pioneered studies on high altitude physiology and the physiological and anatomical mechanisms of adaptation to high elevations. Forty years later Dr Carlos Monge, a Peruvian physiologist, reported his ideas on this issue. The work of these pioneers was summarized early this century (<a href="./references#CD012983-bbs2-0138" title="Rodríguez de RomoAC . Daniel Vergara Lope and Carlos Monge Medrano: two pioneers of high altitude medicine. High Altitude Medicine &amp; Biology2002;3(3):299‐309. [PUBMED: 12396886] ">Rodríguez de Romo 2002</a>). Both the physiology and pathophysiology of high altitude have recently been widely reviewed (<a href="./references#CD012983-bbs2-0080" title="BärtschP , GibbsJS . Effect of altitude on the heart and the lungs. Circulation2007;116(19):2191‐202. [PUBMED: 17984389] ">Bärtsch 2007</a>; <a href="./references#CD012983-bbs2-0085" title="DavisC , HackettP . Advances in the Prevention and Treatment of High Altitude Illness. Emergency Medicine Clinics of North America2017;35(2):241‐60. [PUBMED: 28411926] ">Davis 2017</a>; <a href="./references#CD012983-bbs2-0114" title="LeissnerKB , MahmoodFU . Physiology and pathophysiology at high altitude: considerations for the anesthesiologist. Journal of Anesthesia2009;23(4):543‐53. [PUBMED: 19921365 ] ">Leissner 2009</a>; <a href="./references#CD012983-bbs2-0120" title="LuksAM , SwensonER , BartschP . Acute high‐altitude sickness. European Respiratory Review : an Official Journal of the European Respiratory Society2017;26(143):160096. [PUBMED: 28143879] ">Luks 2017</a>; <a href="./references#CD012983-bbs2-0132" title="PalmerBF . Physiology and pathophysiology with ascent to altitude. American Journal of the Medical Sciences2010;340(1):69‐77. [PUBMED: 20442648] ">Palmer 2010</a>; <a href="./references#CD012983-bbs2-0133" title="ParalikarSJ , ParalikarJH . High‐altitude medicine. Indian Journal of Occupational and Environmental Medicine2010;14(1):6‐12. [PUBMED: 20808661] ">Paralikar 2010</a>). In brief, these reviews confirm both the increase in respiratory rate and increase in haemoglobin concentration on exposure to low oxygen pressure. They identify the rate of ascent, the absolute change in altitude and individual variation in physiology as the primary determinants of whether HAI will develop or not (<a href="./references#CD012983-bbs2-0132" title="PalmerBF . Physiology and pathophysiology with ascent to altitude. American Journal of the Medical Sciences2010;340(1):69‐77. [PUBMED: 20442648] ">Palmer 2010</a>). In addition, HAI is considered an important cause of mountain mortality (<a href="./references#CD012983-bbs2-0155" title="WindsorJS , FirthPG , GrocottMP , RodwayGW , MontgomeryHE . Mountain mortality: a review of deaths that occur during recreational activities in the mountains. Postgraduate Medical Journal2009;85(1004):316‐21. [PUBMED: 19528307] ">Windsor 2009</a>). </p> </section> <section id="CD012983-sec-0019"> <h4 class="title">Acute mountain sickness (AMS) or high altitude cerebral oedema (HACE)</h4> <p>AMS is a disorder with prominent neurological features, characterized by headache, anorexia, nausea and sometimes vomiting, light‐headedness, insomnia, and fatigue (<a href="./references#CD012983-bbs2-0073" title="BaileyDM , BärtschP , KnauthM , BaumgartnerRW . Emerging concepts in acute mountain sickness and high‐altitude cerebral edema: from the molecular to the morphological. Cellular and Molecular Life Sciences2009;66(22):3583‐94. [PUBMED: 19763397] ">Bailey 2009</a>; <a href="./references#CD012983-bbs2-0114" title="LeissnerKB , MahmoodFU . Physiology and pathophysiology at high altitude: considerations for the anesthesiologist. Journal of Anesthesia2009;23(4):543‐53. [PUBMED: 19921365 ] ">Leissner 2009</a>; <a href="./references#CD012983-bbs2-0132" title="PalmerBF . Physiology and pathophysiology with ascent to altitude. American Journal of the Medical Sciences2010;340(1):69‐77. [PUBMED: 20442648] ">Palmer 2010</a>). Headache is the most prevalent symptom of acute mountain sickness. In contrast, HACE is a potentially fatal neurological disorder and it is characterized by altered consciousness or ataxia (<a href="./references#CD012983-bbs2-0073" title="BaileyDM , BärtschP , KnauthM , BaumgartnerRW . Emerging concepts in acute mountain sickness and high‐altitude cerebral edema: from the molecular to the morphological. Cellular and Molecular Life Sciences2009;66(22):3583‐94. [PUBMED: 19763397] ">Bailey 2009</a>; <a href="./references#CD012983-bbs2-0102" title="HackettPH , RoachRC . High altitude cerebral edema. High Altitude Medicine &amp; Biology2004;5(2):136‐46. [PUBMED: 15265335] ">Hackett 2004</a>; <a href="./references#CD012983-bbs2-0107" title="ImrayC , WrightA , SubudhiA , RoachR . Acute mountain sickness: pathophysiology, prevention, and treatment. Progress in Cardiovascular Diseases2010;52(6):467‐84. [PUBMED: 20417340] ">Imray 2010</a>), or both, in an individual with AMS. If left untreated, HACE can result in death due to cerebral oedema (<a href="./references#CD012983-bbs2-0073" title="BaileyDM , BärtschP , KnauthM , BaumgartnerRW . Emerging concepts in acute mountain sickness and high‐altitude cerebral edema: from the molecular to the morphological. Cellular and Molecular Life Sciences2009;66(22):3583‐94. [PUBMED: 19763397] ">Bailey 2009</a>). HACE is widely viewed as the end stage of AMS and is normally preceded by symptoms of AMS, which suggest a similar pathophysiological process (<a href="./references#CD012983-bbs2-0073" title="BaileyDM , BärtschP , KnauthM , BaumgartnerRW . Emerging concepts in acute mountain sickness and high‐altitude cerebral edema: from the molecular to the morphological. Cellular and Molecular Life Sciences2009;66(22):3583‐94. [PUBMED: 19763397] ">Bailey 2009</a>; <a href="./references#CD012983-bbs2-0107" title="ImrayC , WrightA , SubudhiA , RoachR . Acute mountain sickness: pathophysiology, prevention, and treatment. Progress in Cardiovascular Diseases2010;52(6):467‐84. [PUBMED: 20417340] ">Imray 2010</a>; <a href="./references#CD012983-bbs2-0132" title="PalmerBF . Physiology and pathophysiology with ascent to altitude. American Journal of the Medical Sciences2010;340(1):69‐77. [PUBMED: 20442648] ">Palmer 2010</a>). It has been suggested that both syndromes could share a common pathophysiology linked by intracranial hypertension (<a href="./references#CD012983-bbs2-0073" title="BaileyDM , BärtschP , KnauthM , BaumgartnerRW . Emerging concepts in acute mountain sickness and high‐altitude cerebral edema: from the molecular to the morphological. Cellular and Molecular Life Sciences2009;66(22):3583‐94. [PUBMED: 19763397] ">Bailey 2009</a>; <a href="./references#CD012983-bbs2-0085" title="DavisC , HackettP . Advances in the Prevention and Treatment of High Altitude Illness. Emergency Medicine Clinics of North America2017;35(2):241‐60. [PUBMED: 28411926] ">Davis 2017</a>; <a href="./references#CD012983-bbs2-0110" title="KallenbergK , BaileyDM , ChristS , MohrA , RoukensR , MenoldE , et al. Magnetic resonance imaging evidence of cytotoxic cerebral edema in acute mountain sickness. Journal of Cerebral Blood Flow and Metabolism2007;27(5):1064‐71. [PUBMED: 17024110] ">Kallenberg 2007</a>; <a href="./references#CD012983-bbs2-0120" title="LuksAM , SwensonER , BartschP . Acute high‐altitude sickness. European Respiratory Review : an Official Journal of the European Respiratory Society2017;26(143):160096. [PUBMED: 28143879] ">Luks 2017</a>; <a href="./references#CD012983-bbs2-0032" title="MairerK , GobelM , DefrancescoM , WilleM , MessnerH , LoizidesA , et al. MRI evidence: acute mountain sickness is not associated with cerebral edema formation during simulated high altitude. PloS One2012;7(11):e50334. [PUBMED: 23226263] ">Mairer 2012</a>; <a href="./references#CD012983-bbs2-0143" title="SchoonmanGG , SandorPS , NirkkoAC , LangeT , JaermannT , DydakU , et al. Hypoxia‐induced acute mountain sickness is associated with intracellular cerebral edema: a 3 T magnetic resonance imaging study. Journal of Cerebral Blood Flow and Metabolism2008;28(1):198‐206. [PUBMED: 17519973] ">Schoonman 2008</a>; <a href="./references#CD012983-bbs2-0154" title="WilsonMH , NewmanS , ImrayCH . The cerebral effects of ascent to high altitudes. Lancet Neurology2009;8(2):175‐91. [PUBMED: 19161909] ">Wilson 2009</a>). The severity of AMS can be scored using questionnaires such as the Lake Louise Questionnaire, Environmental Symptoms Questionnaire, or by the use of a simple analogue scale (<a href="./references#CD012983-bbs2-0107" title="ImrayC , WrightA , SubudhiA , RoachR . Acute mountain sickness: pathophysiology, prevention, and treatment. Progress in Cardiovascular Diseases2010;52(6):467‐84. [PUBMED: 20417340] ">Imray 2010</a>). Headache is a very common symptom at altitude and some authors have suggested it could be viewed as a distinct clinical entity. </p> <p>The definition of AMS seems to be problematic, as it will vary greatly between studies. A Lake Louise Score greater than 2 (including headache) is not equivalent to a criterion score of 0.70 with AMS‐C (cerebral) from the Environmental Symptoms Questionnaire (<a href="./references#CD012983-bbs2-0121" title="MaggioriniM , MullerA , HofstetterD , BartschP , OelzO . Assessment of acute mountain sickness by different score protocols in the Swiss Alps. Aviation, Space, and Environmental Medicine1998;69(12):1186‐92. [PUBMED: 9856545] ">Maggiorini 1998</a>). The value of the AMS‐R score is questionable for diagnosing AMS (<a href="./references#CD012983-bbs2-0087" title="DumontL , MardirosoffC , TramèrMR . Efficacy and harm of pharmacological prevention of acute mountain sickness: quantitative systematic review. BMJ2000;321(7256):267‐72. [PUBMED: 10915127] ">Dumont 2000</a>). Pathophysiology with a focus on the molecular basis of AMS and HACE has been widely described by <a href="./references#CD012983-bbs2-0073" title="BaileyDM , BärtschP , KnauthM , BaumgartnerRW . Emerging concepts in acute mountain sickness and high‐altitude cerebral edema: from the molecular to the morphological. Cellular and Molecular Life Sciences2009;66(22):3583‐94. [PUBMED: 19763397] ">Bailey 2009</a>; and advances in the genetics, molecular mechanisms, and physiology that underpin them have been extensively described by <a href="./references#CD012983-bbs2-0154" title="WilsonMH , NewmanS , ImrayCH . The cerebral effects of ascent to high altitudes. Lancet Neurology2009;8(2):175‐91. [PUBMED: 19161909] ">Wilson 2009</a>. This review will treat headache as a common and early symptom of AMS. Indeed, the exact definition of what constitutes AMS will vary when using different scoring systems and when interpreted by different authors. </p> </section> <section id="CD012983-sec-0020"> <h4 class="title">High altitude pulmonary oedema (HAPE)</h4> <p>HAPE is a non‐cardiogenic pulmonary oedema (<a href="./references#CD012983-bbs2-0116" title='LuksAM . Do we have a "best practice" for treating high altitude pulmonary edema?. High Altitude Medicine &amp; Biology2008;9(2):111‐4. [PUBMED: 18578641] '>Luks 2008a</a>; <a href="./references#CD012983-bbs2-0141" title="SchoeneRB . Unraveling the mechanism of high altitude pulmonary edema. High Altitude Medicine &amp; Biology2004;5(2):125‐35. [PUBMED: 15265334] ">Schoene 2004</a>; <a href="./references#CD012983-bbs2-0148" title="StreamJO , GrissomCK . Update on high‐altitude pulmonary edema: pathogenesis, prevention, and treatment. Wilderness &amp; Environmental Medicine2008;19(4):293‐303. [PUBMED: 19099331] ">Stream 2008</a>). It is characterized by cough, progressive dyspnoea with exertion, and decreased exercise tolerance, generally developing within two to four days after arrival at high altitude (<a href="./references#CD012983-bbs2-0132" title="PalmerBF . Physiology and pathophysiology with ascent to altitude. American Journal of the Medical Sciences2010;340(1):69‐77. [PUBMED: 20442648] ">Palmer 2010</a>; <a href="./references#CD012983-bbs2-0148" title="StreamJO , GrissomCK . Update on high‐altitude pulmonary edema: pathogenesis, prevention, and treatment. Wilderness &amp; Environmental Medicine2008;19(4):293‐303. [PUBMED: 19099331] ">Stream 2008</a>). It is rare after one week of acclimatization at a particular altitude (<a href="./references#CD012983-bbs2-0122" title="MaggioriniM . Prevention and treatment of high‐altitude pulmonary edema. Progress in Cardiovascular Diseases2010;52(6):500‐6. [PUBMED: 20417343] ">Maggiorini 2010</a>; <a href="./references#CD012983-bbs2-0132" title="PalmerBF . Physiology and pathophysiology with ascent to altitude. American Journal of the Medical Sciences2010;340(1):69‐77. [PUBMED: 20442648] ">Palmer 2010</a>). Hypoxia is the trigger that results in a complex cascade of events leading to HAPE (<a href="./references#CD012983-bbs2-0148" title="StreamJO , GrissomCK . Update on high‐altitude pulmonary edema: pathogenesis, prevention, and treatment. Wilderness &amp; Environmental Medicine2008;19(4):293‐303. [PUBMED: 19099331] ">Stream 2008</a>). Essentially, HAPE is due to a "persistent imbalance between the forces that drive water into the airspace and the biologic mechanisms for its removal" (<a href="./references#CD012983-bbs2-0139" title="ScherrerU , RexhajE , JayetPY , AllemannY , SartoriC . New insights in the pathogenesis of high‐altitude pulmonary edema. Progress in Cardiovascular Diseases2010;52(6):485‐92. [PUBMED: 20417341] ">Scherrer 2010</a>); and the hallmark of this condition is hypoxic pulmonary hypertension. The hypertension may be mediated via at least four potential mechanisms: defective pulmonary nitric oxide synthesis; exaggerated endothelin‐1 synthesis; exaggerated sympathetic activation; and a defect in alveolar transepithelial sodium transport (<a href="./references#CD012983-bbs2-0139" title="ScherrerU , RexhajE , JayetPY , AllemannY , SartoriC . New insights in the pathogenesis of high‐altitude pulmonary edema. Progress in Cardiovascular Diseases2010;52(6):485‐92. [PUBMED: 20417341] ">Scherrer 2010</a>). An extensive review of pulmonary hypertension induced by HAI is reported by <a href="./references#CD012983-bbs2-0134" title="PashaMA , NewmanJH . High‐altitude disorders: pulmonary hypertension: pulmonary vascular disease: the global perspective. Chest2010;137 Suppl(6):13S‐19S. [PUBMED: 20522576] ">Pasha 2010</a>. </p> </section> <section id="CD012983-sec-0021"> <h4 class="title">Epidemiology of acute HAI</h4> <p>It has been estimated that 84% of people who fly directly to 3860 m are affected by AMS (<a href="./references#CD012983-bbs2-0129" title="MurdochDR . Altitude Illness Among Tourists Flying to 3740 Meters Elevation in the Nepal Himalayas. Journal of travel medicine1995;2(4):255‐6. [PUBMED: 9815403] ">Murdoch 1995</a>). The risk of HACE and HAPE is much lower than for AMS, with estimates in the range of 0.1% to 4.0% (<a href="./references#CD012983-bbs2-0074" title="BasnyatB , MurdochDR . High‐altitude illness. Lancet2003;361(9373):1967‐74. [PUBMED: 12801752] ">Basnyat 2003</a>). The rate of ascent, altitude reached (especially the sleeping altitude), and individual susceptibility have been proposed as the most important risk factors for the development of HAI conditions (<a href="./references#CD012983-bbs2-0074" title="BasnyatB , MurdochDR . High‐altitude illness. Lancet2003;361(9373):1967‐74. [PUBMED: 12801752] ">Basnyat 2003</a>; <a href="./references#CD012983-bbs2-0140" title="SchneiderM , BernaschD , WeymannJ , HolleR , BartschP . Acute mountain sickness: influence of susceptibility, preexposure, and ascent rate. Medicine and Science in Sports and Exercise2002;34(12):1886‐91. [PUBMED: 12471292] ">Schneider 2002</a>). Other presumptive risk factors are history of HAI and permanent residence lower than 900 m, exertion in children and adults (<a href="./references#CD012983-bbs2-0074" title="BasnyatB , MurdochDR . High‐altitude illness. Lancet2003;361(9373):1967‐74. [PUBMED: 12801752] ">Basnyat 2003</a>), obesity (<a href="./references#CD012983-bbs2-0136" title="Ri‐LiG , ChasePJ , WitkowskiS , WyrickBL , StoneJA , LevineBD , et al. Obesity: associations with acute mountain sickness. Annals of Internal Medicine2003;139(4):253‐7. [PUBMED: 12965980] ">Ri‐Li 2003</a>), and coronary heart disease (<a href="./references#CD012983-bbs2-0086" title="DehnertC , BartschP . Can patients with coronary heart disease go to high altitude?. High Altitude Medicine &amp; Biology2010;11(3):183‐8. [PUBMED: 20919884] ">Dehnert 2010</a>). It is advisable that those with asthma make sure that their condition is well controlled before they undertake exertion at altitude (<a href="./references#CD012983-bbs2-0081" title="Committee to Advise on Tropical Medicine and Travel (CATMAT). Statement on high‐altitude illnesses. An Advisory Committee Statement (ACS). Canada Communicable Disease Report = Relevé des maladies transmissibles au Canada2007;33(ACS‐5):1‐20. [PUBMED: 17520777] ">CATMAT 2007</a>). </p> <p>See <a href="./appendices#CD012983-sec-0113">Appendix 2</a> for other medical terms. </p> </section> </section> <section id="CD012983-sec-0022"> <h3 class="title" id="CD012983-sec-0022">Description of the intervention</h3> <p>The risk of high altitude illness (HAI) begins with a non‐acclimatized subject ascending to an altitude higher than 2500 metres (<a href="./references#CD012983-bbs2-0090" title="FlahertyGT , KennedyKM . Preparing patients for travel to high altitude: advice on travel health and chemoprophylaxis. British Journal of General Practice : the Journal of the Royal College of General Practitioners2016;66(642):e62‐4. [PUBMED: 26719484] ">Flaherty 2016</a>; <a href="./references#CD012983-bbs2-0111" title="KayserB , DumontL , LysakowskiC , CombescureC , HallerG , TramerMR . Reappraisal of acetazolamide for the prevention of acute mountain sickness: a systematic review and meta‐analysis. High Altitude Medicine &amp; Biology2012;13(2):82‐92. [PUBMED: 22724610] ">Kayser 2012</a>; <a href="./references#CD012983-bbs2-0112" title="KhodaeeM , GrotheHL , SeyfertJH , VanBaakK . Athletes at high altitude. Sports Health2016;8(2):126‐32. [PUBMED: 26863894] ">Khodaee 2016</a>; <a href="./references#CD012983-bbs2-0115" title="LowEV , AveryAJ , GuptaV , SchedlbauerA , GrocottMP . Identifying the lowest effective dose of acetazolamide for the prophylaxis of acute mountain sickness: systematic review and meta‐analysis. BMJ (Clinical research ed.)2012;345:e6779. [PUBMED: 23081689] ">Low 2012</a>; <a href="./references#CD012983-bbs2-0133" title="ParalikarSJ , ParalikarJH . High‐altitude medicine. Indian Journal of Occupational and Environmental Medicine2010;14(1):6‐12. [PUBMED: 20808661] ">Paralikar 2010</a>). However, a susceptible individual may develop acute mountain sickness (AMS) at intermediate altitude such as 2100 metres (<a href="./references#CD012983-bbs2-0085" title="DavisC , HackettP . Advances in the Prevention and Treatment of High Altitude Illness. Emergency Medicine Clinics of North America2017;35(2):241‐60. [PUBMED: 28411926] ">Davis 2017</a>). Several interventions to prevent HAI conditions, especially AMS, have been described, compiled, and published in guidelines and consensus statements (<a href="./references#CD012983-bbs2-0081" title="Committee to Advise on Tropical Medicine and Travel (CATMAT). Statement on high‐altitude illnesses. An Advisory Committee Statement (ACS). Canada Communicable Disease Report = Relevé des maladies transmissibles au Canada2007;33(ACS‐5):1‐20. [PUBMED: 17520777] ">CATMAT 2007</a>; <a href="./references#CD012983-bbs2-0090" title="FlahertyGT , KennedyKM . Preparing patients for travel to high altitude: advice on travel health and chemoprophylaxis. British Journal of General Practice : the Journal of the Royal College of General Practitioners2016;66(642):e62‐4. [PUBMED: 26719484] ">Flaherty 2016</a>; <a href="./references#CD012983-bbs2-0111" title="KayserB , DumontL , LysakowskiC , CombescureC , HallerG , TramerMR . Reappraisal of acetazolamide for the prevention of acute mountain sickness: a systematic review and meta‐analysis. High Altitude Medicine &amp; Biology2012;13(2):82‐92. [PUBMED: 22724610] ">Kayser 2012</a>; <a href="./references#CD012983-bbs2-0112" title="KhodaeeM , GrotheHL , SeyfertJH , VanBaakK . Athletes at high altitude. Sports Health2016;8(2):126‐32. [PUBMED: 26863894] ">Khodaee 2016</a>; <a href="./references#CD012983-bbs2-0115" title="LowEV , AveryAJ , GuptaV , SchedlbauerA , GrocottMP . Identifying the lowest effective dose of acetazolamide for the prophylaxis of acute mountain sickness: systematic review and meta‐analysis. BMJ (Clinical research ed.)2012;345:e6779. [PUBMED: 23081689] ">Low 2012</a>; <a href="./references#CD012983-bbs2-0118" title="LuksAM , McIntoshSE , GrissomCK , AuerbachPS , RodwayGW , SchoeneRB , et al. Wilderness Medical Society consensus guidelines for the prevention and treatment of acute altitude illness. Wilderness &amp; Environmental Medicine2010;21(2):146‐55. [PUBMED: 20591379] ">Luks 2010</a>; <a href="./references#CD012983-bbs2-0137" title="RitchieND , BaggottAV , Andrew ToddWT . Acetazolamide for the prevention of acute mountain sickness‐‐a systematic review and meta‐analysis. Journal of Travel Medicine2012;19(5):298‐307. [PUBMED: 22943270] ">Ritchie 2012</a>; <a href="./references#CD012983-bbs2-0144" title="SeupaulRA , WelchJL , MalkaST , EmmettTW . Pharmacologic prophylaxis for acute mountain sickness: a systematic shortcut review. Annals of Emergency Medicine2012;59(4):307‐317.e1. [PUBMED: 22153998] ">Seupaul 2012</a>; <a href="./references#CD012983-bbs2-0158" title="ZafrenK . Prevention of high altitude illness. Travel Medicine and Infectious Disease2014;12(1):29‐39. [PUBMED: 24393671] ">Zafren 2014</a>). Interventions for HAI prevention can be classified as pharmacological and non‐pharmacological (<a href="./references#CD012983-bbs2-0078" title="BärtschP . Treatment of high altitude diseases without drugs. International Journal of Sports Medicine1992;13 Suppl 1:71‐4. [PUBMED: 1483799] ">Bärtsch 1992</a>; <a href="./references#CD012983-bbs2-0118" title="LuksAM , McIntoshSE , GrissomCK , AuerbachPS , RodwayGW , SchoeneRB , et al. Wilderness Medical Society consensus guidelines for the prevention and treatment of acute altitude illness. Wilderness &amp; Environmental Medicine2010;21(2):146‐55. [PUBMED: 20591379] ">Luks 2010</a>; <a href="./references#CD012983-bbs2-0117" title="LuksAM , SwensonER . Medication and dosage considerations in the prophylaxis and treatment of high‐altitude illness. Chest2008;133(3):744‐55. [PUBMED: 18321903] ">Luks 2008b</a>; <a href="./references#CD012983-bbs2-0156" title="WrightA , BreareyS , ImrayC . High hopes at high altitudes: pharmacotherapy for acute mountain sickness and high‐altitude cerebral and pulmonary oedema. Expert Opinion on Pharmacotherapy2008;9(1):119‐27. [PUBMED: 18076343] ">Wright 2008</a>). The Committee to Advise on Tropical Medicine and Travel proposed a consensus for HAI in 2007, describing prevention and treatment approaches among several topics regarding this medical condition (<a href="./references#CD012983-bbs2-0081" title="Committee to Advise on Tropical Medicine and Travel (CATMAT). Statement on high‐altitude illnesses. An Advisory Committee Statement (ACS). Canada Communicable Disease Report = Relevé des maladies transmissibles au Canada2007;33(ACS‐5):1‐20. [PUBMED: 17520777] ">CATMAT 2007</a>). </p> <p>In 2014 the Wilderness Medical Society (WMS) published an update of their 2010 guidelines, detailing prevention and treatment directives for HAI (AMS, HACE, HAPE) (<a href="./references#CD012983-bbs2-0118" title="LuksAM , McIntoshSE , GrissomCK , AuerbachPS , RodwayGW , SchoeneRB , et al. Wilderness Medical Society consensus guidelines for the prevention and treatment of acute altitude illness. Wilderness &amp; Environmental Medicine2010;21(2):146‐55. [PUBMED: 20591379] ">Luks 2010</a>; <a href="./references#CD012983-bbs2-0119" title="LuksAM , McIntoshSE , GrissomCK , AuerbachPS , RodwayGW , SchoeneRB , et al. Wilderness Medical Society practice guidelines for the prevention and treatment of acute altitude illness: 2014 update. Wilderness &amp; Environmental Medicine2014;25(4 Suppl):S4‐14. [PUBMED: 25498261] ">Luks 2014</a>). This guideline was developed by an expert panel that compiled and classified all available evidence on HAI prevention and treatment. Recommendations, based on evidence using the American College of Chest Physicians' strategies, were agreed upon. For AMS and HACE, the experts proposed a risk classification where low‐risk participants are discarded for prevention interventions; for HAPE, pharmacological prophylaxis is recommended for participants with a previous diagnosis of HAI (<a href="./references#CD012983-bbs2-0119" title="LuksAM , McIntoshSE , GrissomCK , AuerbachPS , RodwayGW , SchoeneRB , et al. Wilderness Medical Society practice guidelines for the prevention and treatment of acute altitude illness: 2014 update. Wilderness &amp; Environmental Medicine2014;25(4 Suppl):S4‐14. [PUBMED: 25498261] ">Luks 2014</a>). </p> <p>These previous reviews have not given a clear indication as to which preventative strategies (whether pharmacological or non‐pharmacological) are of most use, nor how one might modify the approach in different situations. For example, while <a href="./references#CD012983-bbs2-0081" title="Committee to Advise on Tropical Medicine and Travel (CATMAT). Statement on high‐altitude illnesses. An Advisory Committee Statement (ACS). Canada Communicable Disease Report = Relevé des maladies transmissibles au Canada2007;33(ACS‐5):1‐20. [PUBMED: 17520777] ">CATMAT 2007</a> suggests that in general the safest method of prevention is graded ascent, it is not always clear which of the alternative strategies is to be preferred if, for some reason, this is not possible, nor what the major adverse effects of combined approaches might be. </p> <p>Previously, we assessed six groups of the most common interventions for the prevention of HAI (<a href="./references#CD012983-bbs2-0131" title="Nieto EstradaVH , Molano FrancoD , MedinaRD , Gonzalez GarayAG , Martí‐CarvajalAJ , Arevalo‐RodriguezI . Interventions for preventing high altitude illness: Part 1. Commonly‐used classes of drugs. Cochrane Database of Systematic Reviews2017, Issue 6. [DOI: 10.1002/14651858.CD009761.pub2] ">Nieto 2017</a>). In this Cochrane Review we assess five classes of pharmacological interventions less commonly recommended for this condition. Those classes are as follows. </p> <p> <ol id="CD012983-list-0001"> <li> <p>Selective 5‐hydroxytryptamine(1) receptor agonist: sumatriptan (<a href="./references#CD012983-bbs2-0003" title="JafarianS , GorouhiF , SalimiS , LotfiJ . Sumatriptan for prevention of acute mountain sickness: randomized clinical trial. Annals of Neurology2007;62(3):273‐7. [PUBMED: 17557349] ">Jafarian 2007</a>). </p> </li> <li> <p>N‐methyl‐D‐aspartate (NMDA) antagonist: magnesium (<a href="./references#CD012983-bbs2-0002" title="DumontL , LysakowskiC , TramerMR , JunodJD , MardirosoffC , TassonyiE , et al. Magnesium for the prevention and treatment of acute mountain sickness. Clinical Science2004;106(3):269‐77. [PUBMED: 14572305] LysakowskiC , VonElmE , DumontL , JunodJD , TassonyiE , KayserB , et al. Effect of magnesium, high altitude and acute mountain sickness on blood flow velocity in the middle cerebral artery. Clinical Science2004;106(3):279‐85. [PUBMED: 14572304] ">Dumont 2004</a>). </p> </li> <li> <p>Endothelin‐1 antagonist: bosentan (<a href="./references#CD012983-bbs2-0127" title="ModestiPA , VanniS , MorabitoM , ModestiA , MarchettaM , GamberiT , et al. Role of endothelin‐1 in exposure to high altitude: Acute Mountain Sickness and Endothelin‐1 (ACME‐1) study. Circulation2006;114(13):1410‐6. [PUBMED: 16982943] ">Modesti 2006</a>). </p> </li> <li> <p>Anticonvulsant drugs: gabapentin (<a href="./references#CD012983-bbs2-0004" title="JafarianS , AbolfazliR , GorouhiF , RezaieS , LotfiJ . Gabapentin for prevention of hypobaric hypoxia‐induced headache: randomized double‐blind clinical trial. Journal of Neurology, Neurosurgery, and Psychiatry2008;79(3):321‐3. [PUBMED: 17965148] ">Jafarian 2008</a>); phenytoin (<a href="./references#CD012983-bbs2-0008" title="WohnsRN , ColpittsM , ClementT , KaruzaA , BlackettWB , FoutchR , et al. Phenytoin and acute mountain sickness on Mount Everest. American Journal of Medicine1986;80(1):32‐6. [PUBMED: 3510539] ">Wohns 1986</a>). </p> </li> <li> <p>Spironolactone (<a href="./references#CD012983-bbs2-0083" title="CurrieTT , CarterPH , ChampionWL , FongG , FrancisJK , McDonaldIH , et al. Spironolactone and acute mountain sickness. Medical Journal of Australia1976;2(5):168‐70. [PUBMED: 979834] ">Currie 1976</a>; <a href="./references#CD012983-bbs2-0005" title="JainSC , SinghMV , SharmaVM , RawalSB , TyagiAK . Amelioration of acute mountain sickness: comparative study of acetazolamide and spironolactone. International Journal of Biometeorology1986;30(4):293‐300. [PUBMED: 3804482] ">Jain 1986</a>; <a href="./references#CD012983-bbs2-0126" title="MeyersDH . Spironolactone prophylaxis of mountain sickness. British Medical Journal1980; Vol. 281, issue 6254:1569. [PUBMED: 7437886] ">Meyers 1980</a>; <a href="./references#CD012983-bbs2-0145" title="SnellJA , CordnerEP . Spironolactone and acute mountain sickness. Medical Journal of Australia1977; Vol. 1, issue 22:828. [PUBMED: 887008] ">Snell 1977</a>; <a href="./references#CD012983-bbs2-0007" title="BasnyatB , HolckPS , PunM , HalversonS , SzawarskiP , GertschJ , et al. Spironolactone does not prevent acute mountain sickness: a prospective, double‐blind, randomized, placebo‐controlled trial by SPACE Trial Group (spironolactone and acetazolamide trial in the prevention of acute mountain sickness group). Wilderness &amp; Environmental Medicine2011;22(1):15‐22. [PUBMED: 21377114] ">SPACE 2011</a>; <a href="./references#CD012983-bbs2-0146" title="No authorslisted . Spironolactone in acute mountain sickness. Lancet1977;1(8016):855. [PUBMED: 67358] ">Spironolactone in acute mountain sickness 1977</a>; <a href="./references#CD012983-bbs2-0150" title="TurnbullG . Spironolactone prophylaxis in mountain sickness. British Medical Journal1980; Vol. 280, issue 6229:1453. [PUBMED: 7427163] ">Turnbull 1980</a>). </p> </li> </ol> </p> </section> <section id="CD012983-sec-0023"> <h3 class="title" id="CD012983-sec-0023">How the intervention might work</h3> <p>Extensive reviews for the pharmacotherapy of HAI have recently been published (<a href="./references#CD012983-bbs2-0122" title="MaggioriniM . Prevention and treatment of high‐altitude pulmonary edema. Progress in Cardiovascular Diseases2010;52(6):500‐6. [PUBMED: 20417343] ">Maggiorini 2010</a>; <a href="./references#CD012983-bbs2-0156" title="WrightA , BreareyS , ImrayC . High hopes at high altitudes: pharmacotherapy for acute mountain sickness and high‐altitude cerebral and pulmonary oedema. Expert Opinion on Pharmacotherapy2008;9(1):119‐27. [PUBMED: 18076343] ">Wright 2008</a>). Below is a list and brief description of the less common classes of drugs that have been suggested to date. <a href="./appendices#CD012983-sec-0114">Appendix 3</a> provides more detail and discusses the potential adverse effects of each class. </p> <p> <ol id="CD012983-list-0002"> <li> <p>Selective 5‐hydroxytryptamine(1) receptor agonist (sumatriptan): a drug of the family of triptans, characterized by having an agonist effect on vascular serotonin 5‐hydroxytryptamine (5‐HT1) receptors located in the blood vessels of the brain. The binding of sumatriptan to the 5‐HT1 receptor constricts specific large cranial blood vessels without compromising cerebral flow (<a href="./references#CD012983-bbs2-0003" title="JafarianS , GorouhiF , SalimiS , LotfiJ . Sumatriptan for prevention of acute mountain sickness: randomized clinical trial. Annals of Neurology2007;62(3):273‐7. [PUBMED: 17557349] ">Jafarian 2007</a>). </p> </li> <li> <p>N‐methyl‐D‐aspartate (NMDA) antagonist: magnesium. NMDA receptors are cell components in glutamate‐dependent neuronal synapses, which regulate the entry of calcium and the potential for excitatory neurons. It has been noticed that, in the presence of prolonged stimulus, NMDA receptors favour the accumulation of calcium in neurons and its consequent degeneration. The antagonistic drugs of NMDA, such as magnesium, block these receptors and prevent calcium entering neurons, as well as decrease the changes in their structure and function (<a href="./references#CD012983-bbs2-0091" title="GathwalaG , KheraA , SinghI . Magnesium therapy in birth asphyxia. Indian Journal of Pediatrics2006;73(3):209‐12. [PUBMED: 16567913] ">Gathwala 2006</a>). </p> </li> <li> <p>Endothelin‐1 antagonist (bosentan): endothelin 1 is a peptide produced in the endothelium, which binds to its receptors in the lung capillaries, and stimulates the growth of smooth muscle and blood vessel contraction, which is increased at high altitude too. Bosentan is a competitive antagonist of endothelin‐1 receptors, which produces vasodilation and decreased pulmonary vascular resistance (<a href="./references#CD012983-bbs2-0075" title="BevacquaRJ , PerroneSV , BortmanG . Endothelin receptor antagonists for pulmonary arterial hypertension [Antagonistas de los receptores de la endotelina para la hipertensión arterial pulmonar]. Insuficiencia Cardiaca2013;8(2):77‐94. [lil‐694728] ">Bevacqua 2013</a>; <a href="./references#CD012983-bbs2-0092" title="GoerreS , WenkM , BärtschP , LüscherTF , NiroomandF , HohenhausE , et al. Endothelin‐1 in pulmonary hypertension associated with high‐altitude exposure. Circulation1995;91(2):359‐64. [PUBMED: 7805238] ">Goerre 1995</a>; <a href="./references#CD012983-bbs2-0157" title="YanagisawaM , KuriharaH , KimuraS , TomobeY , KobayashiM , MitsuiY , et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature1988;332(6163):411‐5. [PUBMED: 2451132] ">Yanagisawa 1988</a>). </p> </li> <li> <p>Anticonvulsant drugs (gabapentin, phenytoin). Gabapentin is a derivative of the neurotransmitter gamma‐aminobutyric acid (GABA) which partially reduces the response to stimulation of the NMDA receptors, preventing development of neuronal excitation and convulsions; it has also been suggested that it may decrease associated pain. Its mechanism of action is currently unknown (<a href="./references#CD012983-bbs2-0082" title="ChengJK , ChiouLC . Mechanisms of the antinociceptive action of gabapentin. Journal of Pharmacological Sciences2006;100(5):471‐86. [PUBMED: 16474201] ">Cheng 2006</a>; <a href="./references#CD012983-bbs2-0123" title="ManeufYP , LuoZD , LeeK . Alpha2delta and the mechanism of action of gabapentin in the treatment of pain. Seminars in Cell and Developmental Biology2006;17(5):565‐70. [PUBMED: 17067834] ">Maneuf 2006</a>; <a href="./references#CD012983-bbs2-0125" title="MathewNT , RapoportA , SaperJ , MagnusL , KlapperJ , RamadanN , et al. Efficacy of gabapentin in migraine prophylaxis. Headache2001;41(2):119‐28. [PUBMED: 11251695] ">Mathew 2001</a>). Phenytoin is an anticonvulsant agent which binds to voltage gated sodium channel, inhibits the entry of sodium into the neuron and slows the release of potassium, which prevents neuronal depolarization and favouring cerebral protection (<a href="./references#CD012983-bbs2-0077" title="BurseRL , LandowneM , YoungAJ , MaherJT . Phenytoin: ineffective against acute mountain sickness. Aviation, Space, and Environmental Medicine1982;53(3):221‐5. [PUBMED: 6764869] ">Burse 1982</a>). </p> </li> <li> <p>Spironolactone is a potassium‐sparing diuretic that acts by antagonism of aldosterone in the distal renal tubules, increasing the secretion of water and sodium and decreasing the excretion of potassium. (<a href="./references#CD012983-bbs2-0001" title="BrookfieldDS , ListonWA , BrownGV . Use of spironolactone in the prevention of acute mountain sickness on Kilimanjaro. East African Medical Journal1977;54(12):689‐91. [PUBMED: 612430] ">Brookfield 1977</a>; <a href="./references#CD012983-bbs2-0083" title="CurrieTT , CarterPH , ChampionWL , FongG , FrancisJK , McDonaldIH , et al. Spironolactone and acute mountain sickness. Medical Journal of Australia1976;2(5):168‐70. [PUBMED: 979834] ">Currie 1976</a>; <a href="./references#CD012983-bbs2-0005" title="JainSC , SinghMV , SharmaVM , RawalSB , TyagiAK . Amelioration of acute mountain sickness: comparative study of acetazolamide and spironolactone. International Journal of Biometeorology1986;30(4):293‐300. [PUBMED: 3804482] ">Jain 1986</a>; <a href="./references#CD012983-bbs2-0126" title="MeyersDH . Spironolactone prophylaxis of mountain sickness. British Medical Journal1980; Vol. 281, issue 6254:1569. [PUBMED: 7437886] ">Meyers 1980</a>; <a href="./references#CD012983-bbs2-0145" title="SnellJA , CordnerEP . Spironolactone and acute mountain sickness. Medical Journal of Australia1977; Vol. 1, issue 22:828. [PUBMED: 887008] ">Snell 1977</a>; <a href="./references#CD012983-bbs2-0146" title="No authorslisted . Spironolactone in acute mountain sickness. Lancet1977;1(8016):855. [PUBMED: 67358] ">Spironolactone in acute mountain sickness 1977</a>; <a href="./references#CD012983-bbs2-0150" title="TurnbullG . Spironolactone prophylaxis in mountain sickness. British Medical Journal1980; Vol. 280, issue 6229:1453. [PUBMED: 7427163] ">Turnbull 1980</a>). </p> </li> </ol> </p> <p>See <a href="./appendices#CD012983-sec-0114">Appendix 3</a> for adverse events of the pharmacological interventions. </p> </section> <section id="CD012983-sec-0024"> <h3 class="title" id="CD012983-sec-0024">Why it is important to do this review</h3> <p>It is important to conduct this systematic review for several reasons.</p> <p> <ol id="CD012983-list-0003"> <li> <p>Many people travel to recreational areas located at high altitude, putting themselves at an increased risk of developing acute HAI. HAI may be severe and life‐threatening, so effective prevention is likely to be of great value both to these visitors to high altitude areas, and to those responsible for their treatment and rescue when required. At the other end of the spectrum, reliable prevention of minor degrees of AMS would greatly enhance the experience of many travellers. Travel to high altitudes may also aggravate underlying illnesses, particularly cardiopulmonary diseases (<a href="./references#CD012983-bbs2-0081" title="Committee to Advise on Tropical Medicine and Travel (CATMAT). Statement on high‐altitude illnesses. An Advisory Committee Statement (ACS). Canada Communicable Disease Report = Relevé des maladies transmissibles au Canada2007;33(ACS‐5):1‐20. [PUBMED: 17520777] ">CATMAT 2007</a>). </p> </li> <li> <p>The true role of the approaches for preventing acute HAI is uncertain (<a href="./references#CD012983-bbs2-0071" title="AdamsJ . Ginkgo biloba and acetazolamide for acute mountain sickness: exclusion of high risk, low status groups perpetuates discrimination and inequalities. BMJ2004;329(7458):171. [PUBMED: 15258082] ">Adams 2004</a>; <a href="./references#CD012983-bbs2-0079" title="BärtschP , BaileyDM , BergerMM , KnauthM , BaumgartnerRW . Acute mountain sickness: controversies and advances. High Altitude Medicine &amp; Biology2004;5(2):110‐2. [PUBMED: 15265333] ">Bärtsch 2004</a>; <a href="./references#CD012983-bbs2-0081" title="Committee to Advise on Tropical Medicine and Travel (CATMAT). Statement on high‐altitude illnesses. An Advisory Committee Statement (ACS). Canada Communicable Disease Report = Relevé des maladies transmissibles au Canada2007;33(ACS‐5):1‐20. [PUBMED: 17520777] ">CATMAT 2007</a>; <a href="./references#CD012983-bbs2-0089" title="ElphickHL , ElphickDA . Ginkgo biloba and acetazolamide for acute mountain sickness: bias in participants may underestimate effectiveness of agents. BMJ2004;329(7458):172. [PUBMED: 15258084 ] ">Elphick 2004</a>), meaning that their clinical effectiveness and safety must be assessed. </p> </li> <li> <p>It is necessary to answer questions such as: are all these interventions equally useful regardless of the type of HAI? Is there reason to believe that some forms are more appropriate for some patients (persons at risk) than others? </p> </li> <li> <p>An updated meta‐analysis on AMS prevention needs to be produced (<a href="./references#CD012983-bbs2-0087" title="DumontL , MardirosoffC , TramèrMR . Efficacy and harm of pharmacological prevention of acute mountain sickness: quantitative systematic review. BMJ2000;321(7256):267‐72. [PUBMED: 10915127] ">Dumont 2000</a>). </p> </li> </ol> </p> <p>Finally, a systematic review including a rigorous assessment of the risk of bias of the most up‐to‐date evidence will help clinicians make informed decisions regarding the use of non‐pharmacological and pharmacological interventions for preventing acute HAI. The protocol of this review included all agents to prevent high altitude illness (<a href="./references#CD012983-bbs2-0159" title="Martí‐Carvajal ArturoJ , HidalgoR , Simancas‐RacinesD . Interventions for preventing high altitude illness. Cochrane Database of Systematic Reviews2012, Issue 4. [DOI: 10.1002/14651858.CD009761] ">Martí‐Carvajal 2012</a>), but we decided to split that review into a series of three publications about the prevention of this condition (Part 1: Commonly used drugs. Part 2: Less commonly used drugs. Part 3: Miscellaneous and non‐pharmacological interventions). The present review is the second in the series of three and includes five classes of the less frequently recommended drugs to prevent acute HAI conditions. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD012983-sec-0025" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD012983-sec-0025"></div> <p>To assess the clinical effectiveness and adverse events of five of the less commonly used pharmacological interventions for preventing acute HAI in participants who are at risk of developing high altitude illness in any setting. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD012983-sec-0026" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD012983-sec-0026"></div> <section id="CD012983-sec-0027"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD012983-sec-0028"> <h4 class="title">Types of studies</h4> <p>We included randomized controlled trials (RCTs) irrespective of publication status (unpublished trials or published as articles, abstracts, or letters), language and country. We applied no restrictions with respect to periods of follow‐up. </p> <p>We excluded quasi‐randomized studies and prospective observational studies for evaluating clinical effectiveness. </p> </section> <section id="CD012983-sec-0029"> <h4 class="title">Types of participants</h4> <p>We included trials involving participants who are at risk of developing high altitude illness (such as AMS or HACE, or HAPE, or both). We included participants with and without a history of high altitude illness. We applied no age or gender restrictions. </p> </section> <section id="CD012983-sec-0030"> <h4 class="title">Types of interventions</h4> <p>The published protocol of this review included all agents to prevent high altitude illness (<a href="./references#CD012983-bbs2-0159" title="Martí‐Carvajal ArturoJ , HidalgoR , Simancas‐RacinesD . Interventions for preventing high altitude illness. Cochrane Database of Systematic Reviews2012, Issue 4. [DOI: 10.1002/14651858.CD009761] ">Martí‐Carvajal 2012</a>). However we decided to split the topic into a series of three publications about the prevention of this condition (See <a href="#CD012983-sec-0140">Differences between protocol and review</a> section). This is the second of three reviews and includes the following five groups of the less common classes of drugs used to prevent acute HAI. </p> <p> <ol id="CD012983-list-0004"> <li> <p>Selective 5‐hydroxytryptamine(1) receptor agonist (sumatriptan).</p> </li> <li> <p>N‐methyl‐D‐aspartate (NMDA) antagonist (magnesium).</p> </li> <li> <p>Endothelin‐1 antagonist (bosentan).</p> </li> <li> <p>Anticonvulsant drugs (gabapentin; phenytoin).</p> </li> <li> <p>Spironolactone.</p> </li> </ol> </p> <p>We included trials where the relevant medication was administered before the beginning of ascent. We excluded trials using these drugs during ascent or after ascent. </p> </section> <section id="CD012983-sec-0031"> <h4 class="title">Types of outcome measures</h4> <p>The following outcome measures were modified from the published protocol (<a href="./references#CD012983-bbs2-0159" title="Martí‐Carvajal ArturoJ , HidalgoR , Simancas‐RacinesD . Interventions for preventing high altitude illness. Cochrane Database of Systematic Reviews2012, Issue 4. [DOI: 10.1002/14651858.CD009761] ">Martí‐Carvajal 2012</a>). This is a change to the protocol and is explained in the <a href="#CD012983-sec-0140">Differences between protocol and review</a> section. </p> <section id="CD012983-sec-0032"> <h5 class="title">Primary outcomes</h5> <p> <ol id="CD012983-list-0005"> <li> <p>Risk of acute mountain sickness (AMS ‒ as defined by each study) at any time</p> </li> </ol> </p> </section> <section id="CD012983-sec-0033"> <h5 class="title">Secondary outcomes</h5> <p> <ol id="CD012983-list-0006"> <li> <p>Risk of high altitude pulmonary oedema (HAPE ‒ as defined by each study) at any time.</p> </li> <li> <p>Risk of high altitude cerebral oedema (HACE ‒ as defined by each study), at any time.</p> </li> <li> <p>Risk of adverse events in general, including paraesthesia, at any time.</p> </li> <li> <p>Differences in HAI/AMS scores at high altitude. We analysed the differences between groups in any measure of AMS severity and between the first to the 48th hour at high altitude. </p> </li> </ol> </p> </section> </section> </section> <section id="CD012983-sec-0034"> <h3 class="title">Search methods for identification of studies</h3> <p>The same search methods were used for the identification of potential studies and are common for the three reviews included in this set. </p> <section id="CD012983-sec-0035"> <h4 class="title">Electronic searches</h4> <p>We identified RCTs through literature searching with systematic and sensitive search strategies as outlined in Chapter 6.4 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD012983-bbs2-0104" title="HigginsJP , GreenS , editor(s) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011</a>). We did not apply restrictions to language or publication status. </p> <p>We searched the following databases for relevant trials.</p> <p> <ol id="CD012983-list-0007"> <li> <p>Cochrane Central Register of Controlled Trials (CENTRAL; 2017, Issue 4) in the Cochrane Library (searched 20 May 2017); </p> </li> <li> <p>MEDLINE (Ovid SP, 1966 to May week 3 2017);</p> </li> <li> <p>Embase (Ovid SP, 1988 to May week 3 2017);</p> </li> <li> <p>LILACS (BIREME, 1982 to May 2017).</p> </li> </ol> </p> <p>We developed a subject‐specific search strategy in MEDLINE and used that as the basis for the search strategies in the other databases listed. Where appropriate, the search strategy was expanded with search terms for identifying RCTs. All search strategies can be found in Appendices 4 to 7 (<a href="./appendices#CD012983-sec-0115">Appendix 4</a>; <a href="./appendices#CD012983-sec-0116">Appendix 5</a>; <a href="./appendices#CD012983-sec-0117">Appendix 6</a>; <a href="./appendices#CD012983-sec-0118">Appendix 7</a>). </p> <p>We scanned the World Health Organization International Clinical Trials Registry Platform (WHO ICTRP) for ongoing and unpublished trials (May 2017; <a href="./appendices#CD012983-sec-0119">Appendix 8</a>). The search strategy was developed in consultation with the Cochrane Anaesthesia, Critical and Emergency Care Group Information Specialist. </p> </section> <section id="CD012983-sec-0036"> <h4 class="title">Searching other resources</h4> <p>We scanned the reference lists and citations of included trials and any relevant systematic reviews that we identified for further references to additional trials. </p> </section> </section> <section id="CD012983-sec-0037"> <h3 class="title" id="CD012983-sec-0037">Data collection and analysis</h3> <p>Data collection and analysis methods were common for the three reviews included in this series. </p> <section id="CD012983-sec-0038"> <h4 class="title">Selection of studies</h4> <p>Two review authors independently assessed each reference identified by the search against the inclusion criteria. We resolved any disagreements by discussion; a third author was consulted as an arbiter if we could not reach agreement. We retrieved in full those references which appeared to meet the inclusion criteria for further independent assessment by the same three review authors. </p> </section> <section id="CD012983-sec-0039"> <h4 class="title">Data extraction and management</h4> <p>We used a pre‐defined form to extract the following data: eligibility criteria, demographics (age, gender, country), rate of ascent (m/h), final altitude reached (m), AMS scale, design study, history of HAI, type of HAI, proposed intervention, and main outcomes, among others; (see <a href="./appendices#CD012983-sec-0120">Appendix 9</a> for details of the data extraction form). For eligible studies, two review authors extracted the data using the selected form. We resolved discrepancies through discussion or, if required, we involved a third author of this review. We entered data into Review Manager 5 (RevMan 5) software and checked it for accuracy. </p> </section> <section id="CD012983-sec-0040"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Three review authors independently assessed risk of bias for each study using the criteria outlined in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD012983-bbs2-0104" title="HigginsJP , GreenS , editor(s) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011</a>). We resolved any disagreement by discussion. We judged the methodological quality of each study using Cochrane’s tool for assessing risk of bias, a two‐part tool that addresses the following six specific domains: random sequence generation; allocation concealment; blinding of participants, personnel, and outcome assessors; incomplete outcome data; selective reporting; and other bias (<a href="./references#CD012983-bbs2-0104" title="HigginsJP , GreenS , editor(s) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011</a>). The first part describes the risk of bias; the second part provides criteria for making judgements about the risk of bias from each of the six domains in the tool (<a href="./appendices#CD012983-sec-0124">Appendix 10</a>). Based on this tool we implemented a 'Risk of bias' worksheet to be filled out for each study. The risk of bias was assessed by two authors in an independent fashion. We resolved any disagreement through consultation with an additional author. We displayed the results by creating a 'Risk of bias' graph and a 'Risk of bias' summary figure using RevMan 5 software, if appropriate. We present the risk of bias in the Results section. Likewise, we provide summary assessments of the risk of bias for each outcome within and across studies. </p> </section> <section id="CD012983-sec-0041"> <h4 class="title">Measures of treatment effect</h4> <p>For dichotomous outcomes (such as risk of AMS or HAPE), we show results as summary risk ratios with 95% confidence intervals (CI). For continuous outcomes (such as differences in AMS scores), we present the results as summary mean differences (MD) or standardized mean differences (SMD) as appropriate, with 95% CI. For individual studies, we used the CS command in STATA 14.0 (<a href="http://www.stata.com/stata14/" target="_blank">www.stata.com/stata14</a>), for estimation of risk ratios with the corresponding 95% CI. This is a change to the protocol (<a href="./references#CD012983-bbs2-0159" title="Martí‐Carvajal ArturoJ , HidalgoR , Simancas‐RacinesD . Interventions for preventing high altitude illness. Cochrane Database of Systematic Reviews2012, Issue 4. [DOI: 10.1002/14651858.CD009761] ">Martí‐Carvajal 2012</a>), and is explained in the <a href="#CD012983-sec-0140">Differences between protocol and review</a> section. In addition, because we identified a considerable number of cross‐over trials concerning assessed interventions, we included these studies separately and analysed this information using the criteria outlined in the <i>Cochrane Handbook for Systematic Reviews of Interventions,</i> Chapter 16.4 (<a href="./references#CD012983-bbs2-0088" title="ElbourneDR , AltmanDG , HigginsJP , CurtinF , WorthingtonHV , VailA . Meta‐analyses involving cross‐over trials: methodological issues. International Journal of Epidemiology2002;31(1):140‐9. [PUBMED: 11914310] ">Elbourne 2002</a>; <a href="./references#CD012983-bbs2-0104" title="HigginsJP , GreenS , editor(s) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011</a>; <a href="./references#CD012983-bbs2-0147" title="StedmanMR , CurtinF , ElbourneDR , KesselheimAS , BrookhartMA . Meta‐analyses involving cross‐over trials: methodological issues. International Journal of Epidemiology2011;40(6):1732‐4. [PUBMED: 20026595] ">Stedman 2011</a>), specially related to estimation of Mantel‐Haenszel odds ratio (OR) for paired outcomes. </p> </section> <section id="CD012983-sec-0042"> <h4 class="title">Unit of analysis issues</h4> <p><a href="./references#CD012983-bbs2-0159" title="Martí‐Carvajal ArturoJ , HidalgoR , Simancas‐RacinesD . Interventions for preventing high altitude illness. Cochrane Database of Systematic Reviews2012, Issue 4. [DOI: 10.1002/14651858.CD009761] ">Martí‐Carvajal 2012</a> (the published protocol) did not include considerations about any unit of analysis issues. However, we identified 12 cross‐over studies in our search strategies and they were included in the analyses, but separate from the parallel studies. In brief, we used the methods recommended by Elbourne (<a href="./references#CD012983-bbs2-0088" title="ElbourneDR , AltmanDG , HigginsJP , CurtinF , WorthingtonHV , VailA . Meta‐analyses involving cross‐over trials: methodological issues. International Journal of Epidemiology2002;31(1):140‐9. [PUBMED: 11914310] ">Elbourne 2002</a>; <a href="./references#CD012983-bbs2-0147" title="StedmanMR , CurtinF , ElbourneDR , KesselheimAS , BrookhartMA . Meta‐analyses involving cross‐over trials: methodological issues. International Journal of Epidemiology2011;40(6):1732‐4. [PUBMED: 20026595] ">Stedman 2011</a>). This is a change to the protocol (<a href="./references#CD012983-bbs2-0159" title="Martí‐Carvajal ArturoJ , HidalgoR , Simancas‐RacinesD . Interventions for preventing high altitude illness. Cochrane Database of Systematic Reviews2012, Issue 4. [DOI: 10.1002/14651858.CD009761] ">Martí‐Carvajal 2012</a>), and is explained in the <a href="#CD012983-sec-0140">Differences between protocol and review</a> section. </p> </section> <section id="CD012983-sec-0043"> <h4 class="title">Dealing with missing data</h4> <p>For all outcomes we carried out analyses on an intention‐to‐treat (ITT) basis as far as possible (i.e. we attempted to include all randomized participants in the denominator of the assessed groups in the analyses). Due to the fact that we included studies with missing information (especially standard deviations) or data not suitable for planned analyses, we followed the methods recommended by the <i>Cochrane Handbook for Systematic Reviews of Interventions,</i> Chapter 16.1.3 (<a href="./references#CD012983-bbs2-0104" title="HigginsJP , GreenS , editor(s) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011</a>). In brief, we transformed median values and their interquartile ranges or range extracted from included studies to means and standard deviations according to Wan and colleagues (<a href="./references#CD012983-bbs2-0106" title="HozoSP , DjulbegovicB , HozoI . Estimating the mean and variance from the median, range, and the size of a sample. BMC Medical Research Methodology2005;5:13. [PUBMED: 15840177] ">Hozo 2005</a>; <a href="./references#CD012983-bbs2-0151" title="WanX , WangW , LiuJ , TongT . Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range. BMC Medical Research Methodology2014;14:135. [PUBMED: 25524443] ">Wan 2014</a>). This is a change to the protocol (<a href="./references#CD012983-bbs2-0159" title="Martí‐Carvajal ArturoJ , HidalgoR , Simancas‐RacinesD . Interventions for preventing high altitude illness. Cochrane Database of Systematic Reviews2012, Issue 4. [DOI: 10.1002/14651858.CD009761] ">Martí‐Carvajal 2012</a>), and is explained in the <a href="#CD012983-sec-0140">Differences between protocol and review</a> section. </p> </section> <section id="CD012983-sec-0044"> <h4 class="title">Assessment of heterogeneity</h4> <p>We used the I² statistic to measure statistical heterogeneity among the trials in each analysis. When we identified substantial heterogeneity, we explored it by prespecified subgroup analysis. The I² statistic describes the percentage of total variation across trials due to heterogeneity rather than sampling error (<a href="./references#CD012983-bbs2-0103" title="HigginsJPT , ThompsonSG , DeeksJJ , AltmanDG . Measuring inconsistency in meta‐analyses. BMJ2003;327(7414):557‐60. [PUBMED: 12958120] ">Higgins 2003</a>). We considered there to be significant statistical heterogeneity if I² was greater than 50% (<a href="./references#CD012983-bbs2-0104" title="HigginsJP , GreenS , editor(s) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011</a>). We assessed clinical and methodological diversity of the included studies in a comparison for sufficient homogeneity before choosing to estimate summary effect sizes. </p> </section> <section id="CD012983-sec-0045"> <h4 class="title">Assessment of reporting biases</h4> <p>We planned to assess whether the review is subject to publication bias by using a funnel plot to graphically illustrate variability between trials. If asymmetry had been detected, we planned to explore causes other than publication bias. We planned to perform a funnel plot if we included 10 or more RCTs for comparison. However, due to scarcity of information we were not able to perform the mentioned analysis. This is a change to the protocol (<a href="./references#CD012983-bbs2-0159" title="Martí‐Carvajal ArturoJ , HidalgoR , Simancas‐RacinesD . Interventions for preventing high altitude illness. Cochrane Database of Systematic Reviews2012, Issue 4. [DOI: 10.1002/14651858.CD009761] ">Martí‐Carvajal 2012</a>), and is explained in the <a href="#CD012983-sec-0140">Differences between protocol and review</a> section. </p> </section> <section id="CD012983-sec-0046"> <h4 class="title">Data synthesis</h4> <p>We summarized the findings using the random‐effects (DerSimonian–Laird) model. We carried out statistical analyses using RevMan 5 (<a href="./references#CD012983-bbs2-0135" title="Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">Review Manager 2014</a>). We accepted important differences where the effect size 95% confidence limits do not cross the value of no difference between groups. We planned to apply trial sequential analysis (TSA), as cumulative meta‐analyses are at risk of producing random errors due to sparse data and repetitive testing of the accumulating data (<a href="./references#CD012983-bbs2-0076" title="BrokJ , ThorlundK , WetterslevJ , GluudC . Apparently conclusive meta‐analyses may be inconclusive‐‐Trial sequential analysis adjustment of random error risk due to repetitive testing of accumulating data in apparently conclusive neonatal meta‐analyses. International Journal of Epidemiology2009;38(1):287‐98. [PUBMED: 18824466] ">Brok 2009</a>; <a href="./references#CD012983-bbs2-0113" title="LanKKG , DemetsD . Discrete sequential boundaries for clinical trials. Biometrika1983;70(3):659‐63. [DOI: 10.1093/biomet/70.3.659] ">Lan 1983</a>; <a href="./references#CD012983-bbs2-0149" title="ThorlundK , DevereauxPJ , WetterslevJ , GuyattG , IoannidisJP , ThabaneL , et al. Can trial sequential monitoring boundaries reduce spurious inferences from meta‐analyses?. International Journal of Epidemiology2009;38(1):276‐86. [PUBMED: 18824467] ">Thorlund 2009</a>; <a href="./references#CD012983-bbs2-0152" title="WetterslevJ , ThorlundK , BrokJ , GluudC . Trial sequential analysis may establish when firm evidence is reached in cumulative meta‐analysis. Journal of Clinical Epidemiology2008;61(1):64‐75. [PUBMED: 18083463] ">Wetterslev 2008</a>; <a href="./references#CD012983-bbs2-0153" title="WetterslevJ , JakobsenJC , GluudC . Trial Sequential Analysis in systematic reviews with meta‐analysis. BMC Medical Research Methodology2017;17(1):39. [PUBMED: 28264661] ">Wetterslev 2017</a>). However, due to the scarcity of data for the assessed comparisons in this review, we decided not to report the TSA results in this case (all of them having only one study). This is a change from the published protocol (<a href="./references#CD012983-bbs2-0159" title="Martí‐Carvajal ArturoJ , HidalgoR , Simancas‐RacinesD . Interventions for preventing high altitude illness. Cochrane Database of Systematic Reviews2012, Issue 4. [DOI: 10.1002/14651858.CD009761] ">Martí‐Carvajal 2012</a>); (see the details in the <a href="#CD012983-sec-0140">Differences between protocol and review</a> section). We will use TSA methods in our update if there are sufficient studies. </p> </section> <section id="CD012983-sec-0047"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We investigated heterogeneity by an informed clinical evaluation of each outcome, combining data only when clinically appropriate. We also investigated statistical heterogeneity using the I² statistic as described above. For the primary outcomes, we considered subgroup analysis for the following factors, as appropriate. </p> <p> <ol id="CD012983-list-0008"> <li> <p>Extreme altitude exposure versus high or very high exposure (high: 1500 to 3500 m; very high: 3500 to 5500 m; and extreme: above 5500 m) (<a href="./references#CD012983-bbs2-0133" title="ParalikarSJ , ParalikarJH . High‐altitude medicine. Indian Journal of Occupational and Environmental Medicine2010;14(1):6‐12. [PUBMED: 20808661] ">Paralikar 2010</a>). </p> </li> <li> <p>Presence or absence of people at high risk of HAI.</p> </li> <li> <p>Presence or absence of significant pre‐existing disease: cardiovascular diseases, chronic obstructive pulmonary disease (COPD), diabetes mellitus. </p> </li> </ol> </p> <p>However, due to scarcity of information we were not able to perform the planned analysis. This is a change to the protocol (<a href="./references#CD012983-bbs2-0159" title="Martí‐Carvajal ArturoJ , HidalgoR , Simancas‐RacinesD . Interventions for preventing high altitude illness. Cochrane Database of Systematic Reviews2012, Issue 4. [DOI: 10.1002/14651858.CD009761] ">Martí‐Carvajal 2012</a>), and is explained in the <a href="#CD012983-sec-0140">Differences between protocol and review</a> section. </p> </section> <section id="CD012983-sec-0048"> <h4 class="title">Sensitivity analysis</h4> <p>We performed a sensitivity analysis comparing the general results versus RCTs with high methodological quality (studies classified as having a 'low risk of bias' (<a href="./references#CD012983-bbs2-0104" title="HigginsJP , GreenS , editor(s) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011</a>)). We chose only three core domains: generation of allocation sequence, incomplete outcome data, and selective reporting bias. However, due to scarcity of information we were not able to perform the planned analysis. This is a change to the protocol (<a href="./references#CD012983-bbs2-0159" title="Martí‐Carvajal ArturoJ , HidalgoR , Simancas‐RacinesD . Interventions for preventing high altitude illness. Cochrane Database of Systematic Reviews2012, Issue 4. [DOI: 10.1002/14651858.CD009761] ">Martí‐Carvajal 2012</a>), and is explained in the <a href="#CD012983-sec-0140">Differences between protocol and review</a> section. </p> <section id="CD012983-sec-0049"> <h5 class="title">'Summary of findings' tables and GRADE</h5> <p>We developed 'Summary of findings' tables for the following comparisons.</p> <p> <ol id="CD012983-list-0009"> <li> <p>Sumatriptan compared with placebo (<a href="./full#CD012983-tbl-0001">summary of findings Table for the main comparison</a>). </p> </li> <li> <p>Magnesium citrate compared with placebo (<a href="./full#CD012983-tbl-0002">summary of findings Table 2</a>). </p> </li> <li> <p>Spironolactone compared with placebo (<a href="./full#CD012983-tbl-0003">summary of findings Table 3</a>). </p> </li> <li> <p>Acetazolamide compared with spironolactone (<a href="./full#CD012983-tbl-0004">summary of findings Table 4</a>). </p> </li> </ol> </p> <p>We highlighted the quality of evidence in four major outcomes: risk of AMS, risk of HAPE, risk of HACE and risk of adverse events. </p> <p>We used the five GRADE criteria (study limitations; consistency of effect; imprecision; indirectness; and publication bias) to assess the quality of evidence relating to the studies that contributed data to the analyses for each of these four outcomes. When we identified an issue that we considered to be serious in each of the five GRADE criteria, we downgraded the quality of evidence by one level; and when we considered the issue to be very serious, we downgraded the quality of evidence by two levels (<a href="./references#CD012983-bbs2-0094" title="GuyattGH , OxmanAD , MontoriV , VistG , KunzR , BrozekJ , et al. GRADE guidelines: 5. Rating the quality of evidence—publication bias. Journal of Clinical Epidemiology2011;64(12):1277‐82. [PUBMED: 21802904] ">Guyatt 2011a</a>; <a href="./references#CD012983-bbs2-0095" title="GuyattG , OxmanAD , AklEA , KunzR , VistG , BrozekJ , et al. GRADE guidelines: 1. Introduction‐GRADE evidence profiles and summary of findings tables. Journal of Clinical Epidemiology2011;64(4):383‐94. [PUBMED: 21195583] ">Guyatt 2011b</a>; <a href="./references#CD012983-bbs2-0096" title="GuyattGH , OxmanAD , KunzR , WoodcockJ , BrozekJ , HelfandM , et al. GRADE guidelines: 8. Rating the quality of evidence—indirectness. Journal of Clinical Epidemiology2011;64(12):1303‐10. [PUBMED: 21802903] ">Guyatt 2011c</a>; <a href="./references#CD012983-bbs2-0097" title="GuyattGH , OxmanAD , KunzR , WoodcockJ , BrozekJ , HelfandM , et al. GRADE guidelines: 7. Rating the quality of evidence—inconsistency. Journal of Clinical Epidemiology2011;64(12):1294‐302. [PUBMED: 21803546] ">Guyatt 2011d</a>; <a href="./references#CD012983-bbs2-0098" title="GuyattGH , OxmanAD , KunzR , BrozekJ , Alonso‐CoelloP , RindD , et al. GRADE guidelines: 6. Rating the quality of evidence—imprecision. Journal of Clinical Epidemiology2011;64(12):1283‐93. [PUBMED: 21839614] ">Guyatt 2011e</a>; <a href="./references#CD012983-bbs2-0099" title="GuyattGH , OxmanAD , VistG , KunzR , BrozekJ , Alonso‐CoelloP , et al. GRADE guidelines: 4. Rating the quality of evidence—study limitations (risk of bias). Journal of Clinical Epidemiology2011;64(4):407‐15. [PUBMED: 21247734] ">Guyatt 2011f</a>; <a href="./references#CD012983-bbs2-0100" title="GuyattGH , OxmanAD , KunzR , AtkinsD , BrozekJ , VistG , et al. GRADE guidelines: 2. Framing the question and deciding on important outcomes. Journal of Clinical Epidemiology2011;64(4):395‐400. [PUBMED: 21194891] ">Guyatt 2011g</a>; <a href="./references#CD012983-bbs2-0101" title="GuyattGH , OxmanAD , SultanS , GlasziouP , AklEA , Alonso‐CoelloP , et al. GRADE guidelines: 9. Rating up the quality of evidence. Journal of Clinical Epidemiology2011;64(12):1311‐6. [PUBMED: 21802902] ">Guyatt 2011h</a>). Whenever we decided to downgrade the quality of evidence from the default high quality, we justified our decisions and described the level of downgrade in the footnotes of the table. We developed the 'Summary of findings' table using a web‐based version of the GRADEpro software<i>(</i><a href="http://www.guidelinedevelopment.org/)" target="_blank">www.guidelinedevelopment.org)</a><i>,</i> according to the methods and recommendations described in Section 8.5 and Chapter 12 of the <i>Cochrane Handbook for Systematic Reviews of Interventions (</i><a href="./references#CD012983-bbs2-0104" title="HigginsJP , GreenS , editor(s) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011</a><i>).</i> </p> </section> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD012983-sec-0050" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD012983-sec-0050"></div> <section id="CD012983-sec-0051"> <h3 class="title">Description of studies</h3> <p>See <a href="./references#CD012983-sec-0142" title="">Characteristics of included studies</a> and <a href="./references#CD012983-sec-0143" title="">Characteristics of excluded studies</a>. </p> <section id="CD012983-sec-0052"> <h4 class="title">Results of the search</h4> <p>Our searches in May 2017 identified a total of 1332 references. After reviewing the references by title and abstract, we selected 174 of the citations to review as full texts (see <a href="#CD012983-fig-0001">Figure 1</a>). After reading the articles we included in this review eight studies (334 participants), distributed in nine references. We excluded 38 studies (distributed in 40 references), and classified a further 12 studies as ongoing, and another 12 studies as awaiting assessment (most of them due to the full text not yet being available). A further 101 studies were not included in the present review: this is because they are due to be included in the other two reviews in this series of three reviews. </p> <div class="figure" id="CD012983-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram." data-id="CD012983-fig-0001" src="/cdsr/doi/10.1002/14651858.CD012983/media/CDSR/CD012983/image_n/nCD012983-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> </div> </section> <section id="CD012983-sec-0053"> <h4 class="title">Included studies</h4> <p>We included eight studies (334 participants) in this review (<a href="./references#CD012983-bbs2-0001" title="BrookfieldDS , ListonWA , BrownGV . Use of spironolactone in the prevention of acute mountain sickness on Kilimanjaro. East African Medical Journal1977;54(12):689‐91. [PUBMED: 612430] ">Brookfield 1977</a>; <a href="./references#CD012983-bbs2-0002" title="DumontL , LysakowskiC , TramerMR , JunodJD , MardirosoffC , TassonyiE , et al. Magnesium for the prevention and treatment of acute mountain sickness. Clinical Science2004;106(3):269‐77. [PUBMED: 14572305] LysakowskiC , VonElmE , DumontL , JunodJD , TassonyiE , KayserB , et al. Effect of magnesium, high altitude and acute mountain sickness on blood flow velocity in the middle cerebral artery. Clinical Science2004;106(3):279‐85. [PUBMED: 14572304] ">Dumont 2004</a>; <a href="./references#CD012983-bbs2-0003" title="JafarianS , GorouhiF , SalimiS , LotfiJ . Sumatriptan for prevention of acute mountain sickness: randomized clinical trial. Annals of Neurology2007;62(3):273‐7. [PUBMED: 17557349] ">Jafarian 2007</a>; <a href="./references#CD012983-bbs2-0004" title="JafarianS , AbolfazliR , GorouhiF , RezaieS , LotfiJ . Gabapentin for prevention of hypobaric hypoxia‐induced headache: randomized double‐blind clinical trial. Journal of Neurology, Neurosurgery, and Psychiatry2008;79(3):321‐3. [PUBMED: 17965148] ">Jafarian 2008</a>; <a href="./references#CD012983-bbs2-0005" title="JainSC , SinghMV , SharmaVM , RawalSB , TyagiAK . Amelioration of acute mountain sickness: comparative study of acetazolamide and spironolactone. International Journal of Biometeorology1986;30(4):293‐300. [PUBMED: 3804482] ">Jain 1986</a>; <a href="./references#CD012983-bbs2-0006" title="LarsenRF , RockPB , FulcoCS , EdelmanB , YoungAJ , CymermanA . Effect of spironolactone on acute mountain sickness. Aviation, Space, and Environmental Medicine1986;57(6):543‐7. [PUBMED: 3718378] ">Larsen 1986</a>; <a href="./references#CD012983-bbs2-0007" title="BasnyatB , HolckPS , PunM , HalversonS , SzawarskiP , GertschJ , et al. Spironolactone does not prevent acute mountain sickness: a prospective, double‐blind, randomized, placebo‐controlled trial by SPACE Trial Group (spironolactone and acetazolamide trial in the prevention of acute mountain sickness group). Wilderness &amp; Environmental Medicine2011;22(1):15‐22. [PUBMED: 21377114] ">SPACE 2011</a>; <a href="./references#CD012983-bbs2-0008" title="WohnsRN , ColpittsM , ClementT , KaruzaA , BlackettWB , FoutchR , et al. Phenytoin and acute mountain sickness on Mount Everest. American Journal of Medicine1986;80(1):32‐6. [PUBMED: 3510539] ">Wohns 1986</a>). The results of <a href="./references#CD012983-bbs2-0002" title="DumontL , LysakowskiC , TramerMR , JunodJD , MardirosoffC , TassonyiE , et al. Magnesium for the prevention and treatment of acute mountain sickness. Clinical Science2004;106(3):269‐77. [PUBMED: 14572305] LysakowskiC , VonElmE , DumontL , JunodJD , TassonyiE , KayserB , et al. Effect of magnesium, high altitude and acute mountain sickness on blood flow velocity in the middle cerebral artery. Clinical Science2004;106(3):279‐85. [PUBMED: 14572304] ">Dumont 2004</a> were published across two separate papers and so is included as a single study. Seven of the eight included studies were parallel trials, while the remaining trial was a cross‐over trial (<a href="./references#CD012983-bbs2-0006" title="LarsenRF , RockPB , FulcoCS , EdelmanB , YoungAJ , CymermanA . Effect of spironolactone on acute mountain sickness. Aviation, Space, and Environmental Medicine1986;57(6):543‐7. [PUBMED: 3718378] ">Larsen 1986</a>). All trials were developed at high altitude. </p> <section id="CD012983-sec-0054"> <h5 class="title">Participants</h5> <p>The participants' ages ranged between 15 and 65 years. Four of the studies included only men (50%; <a href="./references#CD012983-bbs2-0004" title="JafarianS , AbolfazliR , GorouhiF , RezaieS , LotfiJ . Gabapentin for prevention of hypobaric hypoxia‐induced headache: randomized double‐blind clinical trial. Journal of Neurology, Neurosurgery, and Psychiatry2008;79(3):321‐3. [PUBMED: 17965148] ">Jafarian 2008</a>; <a href="./references#CD012983-bbs2-0005" title="JainSC , SinghMV , SharmaVM , RawalSB , TyagiAK . Amelioration of acute mountain sickness: comparative study of acetazolamide and spironolactone. International Journal of Biometeorology1986;30(4):293‐300. [PUBMED: 3804482] ">Jain 1986</a>; <a href="./references#CD012983-bbs2-0006" title="LarsenRF , RockPB , FulcoCS , EdelmanB , YoungAJ , CymermanA . Effect of spironolactone on acute mountain sickness. Aviation, Space, and Environmental Medicine1986;57(6):543‐7. [PUBMED: 3718378] ">Larsen 1986</a>; <a href="./references#CD012983-bbs2-0008" title="WohnsRN , ColpittsM , ClementT , KaruzaA , BlackettWB , FoutchR , et al. Phenytoin and acute mountain sickness on Mount Everest. American Journal of Medicine1986;80(1):32‐6. [PUBMED: 3510539] ">Wohns 1986</a>). Only <a href="./references#CD012983-bbs2-0002" title="DumontL , LysakowskiC , TramerMR , JunodJD , MardirosoffC , TassonyiE , et al. Magnesium for the prevention and treatment of acute mountain sickness. Clinical Science2004;106(3):269‐77. [PUBMED: 14572305] LysakowskiC , VonElmE , DumontL , JunodJD , TassonyiE , KayserB , et al. Effect of magnesium, high altitude and acute mountain sickness on blood flow velocity in the middle cerebral artery. Clinical Science2004;106(3):279‐85. [PUBMED: 14572304] ">Dumont 2004</a> included people with a history of AMS (12.5%). </p> </section> <section id="CD012983-sec-0055"> <h5 class="title">Setting</h5> <p>Two of the eight included studies were undertaken in the USA (25%; <a href="./references#CD012983-bbs2-0005" title="JainSC , SinghMV , SharmaVM , RawalSB , TyagiAK . Amelioration of acute mountain sickness: comparative study of acetazolamide and spironolactone. International Journal of Biometeorology1986;30(4):293‐300. [PUBMED: 3804482] ">Jain 1986</a>; <a href="./references#CD012983-bbs2-0006" title="LarsenRF , RockPB , FulcoCS , EdelmanB , YoungAJ , CymermanA . Effect of spironolactone on acute mountain sickness. Aviation, Space, and Environmental Medicine1986;57(6):543‐7. [PUBMED: 3718378] ">Larsen 1986</a>). The remaining six studies were carried out in Asia (37.5%; <a href="./references#CD012983-bbs2-0004" title="JafarianS , AbolfazliR , GorouhiF , RezaieS , LotfiJ . Gabapentin for prevention of hypobaric hypoxia‐induced headache: randomized double‐blind clinical trial. Journal of Neurology, Neurosurgery, and Psychiatry2008;79(3):321‐3. [PUBMED: 17965148] ">Jafarian 2008</a>; <a href="./references#CD012983-bbs2-0007" title="BasnyatB , HolckPS , PunM , HalversonS , SzawarskiP , GertschJ , et al. Spironolactone does not prevent acute mountain sickness: a prospective, double‐blind, randomized, placebo‐controlled trial by SPACE Trial Group (spironolactone and acetazolamide trial in the prevention of acute mountain sickness group). Wilderness &amp; Environmental Medicine2011;22(1):15‐22. [PUBMED: 21377114] ">SPACE 2011</a>; <a href="./references#CD012983-bbs2-0008" title="WohnsRN , ColpittsM , ClementT , KaruzaA , BlackettWB , FoutchR , et al. Phenytoin and acute mountain sickness on Mount Everest. American Journal of Medicine1986;80(1):32‐6. [PUBMED: 3510539] ">Wohns 1986</a>); and in Europe, Africa and South America (37.5%; <a href="./references#CD012983-bbs2-0001" title="BrookfieldDS , ListonWA , BrownGV . Use of spironolactone in the prevention of acute mountain sickness on Kilimanjaro. East African Medical Journal1977;54(12):689‐91. [PUBMED: 612430] ">Brookfield 1977</a>; <a href="./references#CD012983-bbs2-0002" title="DumontL , LysakowskiC , TramerMR , JunodJD , MardirosoffC , TassonyiE , et al. Magnesium for the prevention and treatment of acute mountain sickness. Clinical Science2004;106(3):269‐77. [PUBMED: 14572305] LysakowskiC , VonElmE , DumontL , JunodJD , TassonyiE , KayserB , et al. Effect of magnesium, high altitude and acute mountain sickness on blood flow velocity in the middle cerebral artery. Clinical Science2004;106(3):279‐85. [PUBMED: 14572304] ">Dumont 2004</a>; <a href="./references#CD012983-bbs2-0003" title="JafarianS , GorouhiF , SalimiS , LotfiJ . Sumatriptan for prevention of acute mountain sickness: randomized clinical trial. Annals of Neurology2007;62(3):273‐7. [PUBMED: 17557349] ">Jafarian 2007</a>). </p> </section> <section id="CD012983-sec-0056"> <h5 class="title">Administration of intervention to prevent HAI conditions</h5> <p>Three of the eight studies provided the intervention less than 24 hours prior to the ascent (37.5%; <a href="./references#CD012983-bbs2-0003" title="JafarianS , GorouhiF , SalimiS , LotfiJ . Sumatriptan for prevention of acute mountain sickness: randomized clinical trial. Annals of Neurology2007;62(3):273‐7. [PUBMED: 17557349] ">Jafarian 2007</a>; <a href="./references#CD012983-bbs2-0004" title="JafarianS , AbolfazliR , GorouhiF , RezaieS , LotfiJ . Gabapentin for prevention of hypobaric hypoxia‐induced headache: randomized double‐blind clinical trial. Journal of Neurology, Neurosurgery, and Psychiatry2008;79(3):321‐3. [PUBMED: 17965148] ">Jafarian 2008</a>; <a href="./references#CD012983-bbs2-0008" title="WohnsRN , ColpittsM , ClementT , KaruzaA , BlackettWB , FoutchR , et al. Phenytoin and acute mountain sickness on Mount Everest. American Journal of Medicine1986;80(1):32‐6. [PUBMED: 3510539] ">Wohns 1986</a>), and four studies between one to three days prior (50%). One trial did not provide information about this issue (<a href="./references#CD012983-bbs2-0007" title="BasnyatB , HolckPS , PunM , HalversonS , SzawarskiP , GertschJ , et al. Spironolactone does not prevent acute mountain sickness: a prospective, double‐blind, randomized, placebo‐controlled trial by SPACE Trial Group (spironolactone and acetazolamide trial in the prevention of acute mountain sickness group). Wilderness &amp; Environmental Medicine2011;22(1):15‐22. [PUBMED: 21377114] ">SPACE 2011</a>). In 25% of the trials, the participants hiked (trekked) to endpoint altitude, and in the remaining studies they used a combination of means of transportation, including cars, trains, and cable cars (75%). </p> </section> <section id="CD012983-sec-0057"> <h5 class="title">Altitude</h5> <p>All of the included studies reached a final altitude of between 3500 and 5895 metres above sea level. The difference between the endpoint and the baseline altitude ranged from 700 to 5120 metres. The most frequent durations for ascent were more than two days (four studies; <a href="./references#CD012983-bbs2-0001" title="BrookfieldDS , ListonWA , BrownGV . Use of spironolactone in the prevention of acute mountain sickness on Kilimanjaro. East African Medical Journal1977;54(12):689‐91. [PUBMED: 612430] ">Brookfield 1977</a>; <a href="./references#CD012983-bbs2-0002" title="DumontL , LysakowskiC , TramerMR , JunodJD , MardirosoffC , TassonyiE , et al. Magnesium for the prevention and treatment of acute mountain sickness. Clinical Science2004;106(3):269‐77. [PUBMED: 14572305] LysakowskiC , VonElmE , DumontL , JunodJD , TassonyiE , KayserB , et al. Effect of magnesium, high altitude and acute mountain sickness on blood flow velocity in the middle cerebral artery. Clinical Science2004;106(3):279‐85. [PUBMED: 14572304] ">Dumont 2004</a>; <a href="./references#CD012983-bbs2-0007" title="BasnyatB , HolckPS , PunM , HalversonS , SzawarskiP , GertschJ , et al. Spironolactone does not prevent acute mountain sickness: a prospective, double‐blind, randomized, placebo‐controlled trial by SPACE Trial Group (spironolactone and acetazolamide trial in the prevention of acute mountain sickness group). Wilderness &amp; Environmental Medicine2011;22(1):15‐22. [PUBMED: 21377114] ">SPACE 2011</a>; <a href="./references#CD012983-bbs2-0008" title="WohnsRN , ColpittsM , ClementT , KaruzaA , BlackettWB , FoutchR , et al. Phenytoin and acute mountain sickness on Mount Everest. American Journal of Medicine1986;80(1):32‐6. [PUBMED: 3510539] ">Wohns 1986</a>). Two studies did not provide any information about these issues (25%; <a href="./references#CD012983-bbs2-0005" title="JainSC , SinghMV , SharmaVM , RawalSB , TyagiAK . Amelioration of acute mountain sickness: comparative study of acetazolamide and spironolactone. International Journal of Biometeorology1986;30(4):293‐300. [PUBMED: 3804482] ">Jain 1986</a>; <a href="./references#CD012983-bbs2-0006" title="LarsenRF , RockPB , FulcoCS , EdelmanB , YoungAJ , CymermanA . Effect of spironolactone on acute mountain sickness. Aviation, Space, and Environmental Medicine1986;57(6):543‐7. [PUBMED: 3718378] ">Larsen 1986</a>). </p> </section> <section id="CD012983-sec-0058"> <h5 class="title">Scale used to assess AMS</h5> <p>The most commonly used scale used was the Lake Louise Score (50%; <a href="./references#CD012983-bbs2-0002" title="DumontL , LysakowskiC , TramerMR , JunodJD , MardirosoffC , TassonyiE , et al. Magnesium for the prevention and treatment of acute mountain sickness. Clinical Science2004;106(3):269‐77. [PUBMED: 14572305] LysakowskiC , VonElmE , DumontL , JunodJD , TassonyiE , KayserB , et al. Effect of magnesium, high altitude and acute mountain sickness on blood flow velocity in the middle cerebral artery. Clinical Science2004;106(3):279‐85. [PUBMED: 14572304] ">Dumont 2004</a>; <a href="./references#CD012983-bbs2-0003" title="JafarianS , GorouhiF , SalimiS , LotfiJ . Sumatriptan for prevention of acute mountain sickness: randomized clinical trial. Annals of Neurology2007;62(3):273‐7. [PUBMED: 17557349] ">Jafarian 2007</a>; <a href="./references#CD012983-bbs2-0004" title="JafarianS , AbolfazliR , GorouhiF , RezaieS , LotfiJ . Gabapentin for prevention of hypobaric hypoxia‐induced headache: randomized double‐blind clinical trial. Journal of Neurology, Neurosurgery, and Psychiatry2008;79(3):321‐3. [PUBMED: 17965148] ">Jafarian 2008</a>; <a href="./references#CD012983-bbs2-0007" title="BasnyatB , HolckPS , PunM , HalversonS , SzawarskiP , GertschJ , et al. Spironolactone does not prevent acute mountain sickness: a prospective, double‐blind, randomized, placebo‐controlled trial by SPACE Trial Group (spironolactone and acetazolamide trial in the prevention of acute mountain sickness group). Wilderness &amp; Environmental Medicine2011;22(1):15‐22. [PUBMED: 21377114] ">SPACE 2011</a>), and the criterion to define AMS onset was a score of 3 points or more in two trials (<a href="./references#CD012983-bbs2-0003" title="JafarianS , GorouhiF , SalimiS , LotfiJ . Sumatriptan for prevention of acute mountain sickness: randomized clinical trial. Annals of Neurology2007;62(3):273‐7. [PUBMED: 17557349] ">Jafarian 2007</a>; <a href="./references#CD012983-bbs2-0004" title="JafarianS , AbolfazliR , GorouhiF , RezaieS , LotfiJ . Gabapentin for prevention of hypobaric hypoxia‐induced headache: randomized double‐blind clinical trial. Journal of Neurology, Neurosurgery, and Psychiatry2008;79(3):321‐3. [PUBMED: 17965148] ">Jafarian 2008</a>). In two studies, the criteria used to define the onset of AMS were unclear (25%; <a href="./references#CD012983-bbs2-0005" title="JainSC , SinghMV , SharmaVM , RawalSB , TyagiAK . Amelioration of acute mountain sickness: comparative study of acetazolamide and spironolactone. International Journal of Biometeorology1986;30(4):293‐300. [PUBMED: 3804482] ">Jain 1986</a>; <a href="./references#CD012983-bbs2-0006" title="LarsenRF , RockPB , FulcoCS , EdelmanB , YoungAJ , CymermanA . Effect of spironolactone on acute mountain sickness. Aviation, Space, and Environmental Medicine1986;57(6):543‐7. [PUBMED: 3718378] ">Larsen 1986</a>). </p> </section> <section id="CD012983-sec-0059"> <h5 class="title">Funding</h5> <p>Only one of the included studies did not provide clear information about the source of funding (12.5%; <a href="./references#CD012983-bbs2-0006" title="LarsenRF , RockPB , FulcoCS , EdelmanB , YoungAJ , CymermanA . Effect of spironolactone on acute mountain sickness. Aviation, Space, and Environmental Medicine1986;57(6):543‐7. [PUBMED: 3718378] ">Larsen 1986</a>). None of the included studies bar <a href="./references#CD012983-bbs2-0004" title="JafarianS , AbolfazliR , GorouhiF , RezaieS , LotfiJ . Gabapentin for prevention of hypobaric hypoxia‐induced headache: randomized double‐blind clinical trial. Journal of Neurology, Neurosurgery, and Psychiatry2008;79(3):321‐3. [PUBMED: 17965148] ">Jafarian 2008</a> declared their possible conflicts of interests (87.5%). For further information refer to the table '<a href="./references#CD012983-sec-0142" title="">Characteristics of included studies</a>' </p> </section> </section> <section id="CD012983-sec-0060"> <h4 class="title">Excluded studies</h4> <p>We excluded 38 studies (40 references) from this series of three reviews (<a href="./references#CD012983-bbs2-0009" title="ModestiPA , VanniS , MorabitoM , ModestiA , MarchettaM , GamberiT , et al. Role of endothelin‐1 in exposure to high altitude: Acute Mountain Sickness and Endothelin‐1 (ACME‐1) study. Circulation2006;114(13):1410‐6. [PUBMED: 16982943] ">ACME‐1 2006</a>; <a href="./references#CD012983-bbs2-0010" title="AgostoniP , SwensonER , FumagalliR , SalvioniaE , CattadoriaG , FarinaS , et al. Acute high‐altitude exposure reduces lung diffusion: Data from the HIGHCARE Alps project. Respiratory Physiology &amp; Neurobiology2013;188(2):223‐8. [PUBMED: 23619193] ">Agostoni 2013</a>; <a href="./references#CD012983-bbs2-0011" title="BartschP , MerkiB , HofstetterD , MaggioriniM , KayserB , OelzO . Treatment of acute mountain‐sickness by simulated descent ‐ a randomized controlled trial. BMJ1993;306(6885):1098‐101. [PUBMED: 8495155] ">Bartsch 1993</a>; <a href="./references#CD012983-bbs2-0012" title="BartschP , MaggiS , KlegerGR , BallmerPE , BaumgartnerRW . Sumatriptan for high‐altitude headache. Lancet1994;344(8934):1445. [PUBMED: 7968111] ">Bartsch 1994</a>; <a href="./references#CD012983-bbs2-0013" title="BiloG , LombardiC , ReveraM , DiazziE , GiulianoA , FainiA , et al. Acetazolamide counteracts ambulatory blood pressure increase under acute exposure to high altitude. High Blood Pressure and Cardiovascular Prevention2011;18(3):118. [EMBASE: 70547750] BiloG , VillafuerteFC , FainiA , Anza‐RamírezC , ReveraM , GiulianoA , et al. Ambulatory blood pressure in untreated and treated hypertensive patients at high altitude: the High Altitude Cardiovascular Research‐Andes study. Hypertension2015;65(6):1266‐72. [PUBMED: 25895588] Bilo , G , VillafuerteF , AnzaC , Revera , GiulianoA , FainiA , et al. Combined antihypertensive treatment and blood pressure responses to acute high altitude exposure in patients with hypertension. HIGHCARE‐ANDES Lowlanders Study. European Heart Journal2011;34(Suppl 1):269‐70. [EMBASE: 71258517] ">Bilo 2015</a>; <a href="./references#CD012983-bbs2-0014" title="BlochKE , TurkAJ , MaggioriniM , HessT , MerzT , BoschMM , et al. Effect of ascent protocol on acute mountain sickness and success at Muztagh Ata, 7546 m. High Altitude Medicine &amp; Biology2009;10(1):25‐32. [PUBMED: 19326598] ">Bloch 2009</a>; <a href="./references#CD012983-bbs2-0015" title="BroomeJR , StonehamMD , BeeleyJM , MilledgeJS , HughesAS . High altitude headache: treatment with ibuprofen. Aviation, Space, and Environmental Medicine1994;65(1):19‐20. [PUBMED: 8117220] ">Broome 1994</a>; <a href="./references#CD012983-bbs2-0016" title="CainSM , DunnJE2 . Low doses of acetazolamide to aid accommodation of men to altitude. Journal of Applied Physiology1966;21(4):1195‐200. [PUBMED: 5916650] ">Cain 1966</a>; <a href="./references#CD012983-bbs2-0017" title='DebevecT , PialouxV , SaugyJ , SchmittL , CejuelaR , MuryP , et al. Prooxidant/Antioxidant balance in Hypoxia: A cross‐over study on normobaric vs. Hypobaric "live high‐train low". PLoS ONE2015;10(9):e0137957. [PUBMED: 26368280] '>Debevec 2015</a>; <a href="./references#CD012983-bbs2-0018" title="DumontL , MardirosoffC , Soto‐DebeufG , TassonyiE . Magnesium and acute mountain sickness. Aviation, Space, and Environmental Medicine1999;70(6):625. [PUBMED: 10373058] ">Dumont 1999</a>; <a href="./references#CD012983-bbs2-0019" title="ForsterP . Methazolamide in acute mountain sickness. Lancet1982;1(8283):1254. [PUBMED: 6123014] ">Forster 1982</a>; <a href="./references#CD012983-bbs2-0020" title="ForwandSA , LandowneM , FollansbeeJN , HansenJE . Effect of acetazolamide on acute mountain sickness. New England Journal of Medicine1968;279(16):839‐45. [PUBMED: 4877992] ">Forwand 1968</a>; <a href="./references#CD012983-bbs2-0021" title="FulcoCS , MuzaSR , BeidlemanBA , DemesR , StaabJE , JonesJE , et al. Effect of repeated normobaric hypoxia exposures during sleep on acute mountain sickness, exercise performance, and sleep during exposure to terrestrial altitude. American Journal of Physiology. Regulatory, Integrative and Comparative Physiology2011;300(2):R428‐36. [PUBMED: 21123763] ">Fulco 2011</a>; <a href="./references#CD012983-bbs2-0022" title="GertschJH , SetoTB , MorJ , OnopaJ . Ginkgo biloba for the prevention of severe acute mountain sickness (AMS) starting one day before rapid ascent. High Altitude Medicine &amp; Biology2002;3(1):29‐37. [PUBMED: 12006162] ">Gertsch 2002</a>; <a href="./references#CD012983-bbs2-0023" title="GrayGW , BryanAC , FrayserR , HoustonCS , RennieID . Control of acute mountain sickness. Aerospace Medicine1971;42(1):81‐4. [PUBMED: 4925130] ">Gray 1971</a>; <a href="./references#CD012983-bbs2-0024" title="HarrisNS , WenzelRP , ThomasSH . High altitude headache: efficacy of acetaminophen vs. ibuprofen in a randomized, controlled trial. Journal of Emergency Medicine2003;24(4):383‐7. [PUBMED: 12745039] ">Harris 2003</a>; <a href="./references#CD012983-bbs2-0025" title="JohnsonTS , RockPB , YoungJB , FulcoCS , TradLA . Hemodynamic and sympathoadrenal responses to altitude in humans: effect of dexamethasone. Aviation, Space, and Environmental Medicine1988;59(3):208‐12. [PUBMED: 3355474] ">Johnson 1988</a>; <a href="./references#CD012983-bbs2-0026" title="JonkAM , van denBergIP , OlfertIM , WrayDW , AraiT , HopkinsSR , et al. Effect of acetazolamide on pulmonary and muscle gas exchange during normoxic and hypoxic exercise. Journal of Physiology2007;579(Pt 3):909‐21. [PUBMED: 17218362] ">Jonk 2007</a>; <a href="./references#CD012983-bbs2-0027" title="KotwalJ , KotwalA , BhallaS , SinghP K , NairV , AuthorA , et al. Effectiveness of homocysteine lowering vitamins in prevention of thrombotic tendency at high altitude area: a randomized field trial. Thrombosis Research2015;136(4):758‐62. [PUBMED: 26319423] ">Kotwal 2015</a>; <a href="./references#CD012983-bbs2-0028" title="LalandeS , SnyderEM , OlsonTP , HulsebusML , OrbanM , SomersVK , et al. The effects of sildenafil and acetazolamide on breathing efficiency and ventilatory control during hypoxic exercise. European Journal of Applied Physiology2009;106(4):509‐15. [PUBMED: 19337745] ">Lalande 2009</a>; <a href="./references#CD012983-bbs2-0029" title="LawleyJS , OliverSJ , MullinsP , MorrisD , JungleeNA , JelleymanC , et al. Optic nerve sheath diameter is not related to high altitude headache: A randomized controlled trial. High Altitude Medicine &amp; Biology2012;13(3):193‐9. [PUBMED: 22994519] ">Lawley 2012</a>; <a href="./references#CD012983-bbs2-0030" title="LevineBD , YoshimuraK , KobayashiT , FukushimaM , ShibamotoT , UedaG . Dexamethasone in the treatment of acute mountain sickness. New England Journal of Medicine1989;321(25):1707‐13. [PUBMED: 2687688] ">Levine 1989</a>; <a href="./references#CD012983-bbs2-0031" title="LiuC , CroftQP , KalidharS , BrooksJT , HerigstadM , SmithTG , et al. Dexamethasone mimics aspects of physiological acclimatization to 8 hours of hypoxia but suppresses plasma erythropoietin. Journal of Applied Physiology2013;114(7):948‐56. [PUBMED: 23393065] ">Liu 2013</a>; <a href="./references#CD012983-bbs2-0032" title="MairerK , GobelM , DefrancescoM , WilleM , MessnerH , LoizidesA , et al. MRI evidence: acute mountain sickness is not associated with cerebral edema formation during simulated high altitude. PloS One2012;7(11):e50334. [PUBMED: 23226263] ">Mairer 2012</a>; <a href="./references#CD012983-bbs2-0033" title="McIntoshIB , PrescottRJ . Acetazolamide in prevention of acute mountain sickness. Journal of International Medical Research1986;14(5):285‐7. [PUBMED: 3533677] ">McIntosh 1986</a>; <a href="./references#CD012983-bbs2-0034" title="PurkayasthaSS , RayUS , AroraBS , ChhabraPC , ThakurL , BandopadhyayP , et al. Acclimatization at high altitude in gradual and acute induction. Journal of Applied Physiology1995;79(2):487‐92. [PUBMED: 7592207] ">Purkayastha 1995</a>; <a href="./references#CD012983-bbs2-0035" title="ReinhartWH , GoerreS , BartschP . Acetazolamide reduces the erythropoietin response to hypoxia at high altitude in humans. Journal of Wilderness Medicine1994;5(3):312‐7. [EMBASE: 24320364] ">Reinhart 1994</a>; <a href="./references#CD012983-bbs2-0036" title="SandovalM , SilvaJ , ParraM , CifuentesF , MaluendaR , EscobarJ . Effects of consumption of antioxidants in altitude exposure [Efectos del consumo de antioxidantes en exposición a altitud]. Boletin Cientifico de la Asociación Chilena de Seguridad2000;2(3):67‐73. [lil‐318088] ">Sandoval 2000</a>; <a href="./references#CD012983-bbs2-0037" title="ScalzoRL , BinnsSE , KlochakAL , GiordanoGR , ParisHLR , SevitsKJ , et al. Methazolamide plus aminophylline abrogates hypoxia‐mediated endurance exercise impairment. High Altitude Medicine &amp; Biology2015;16:331‐42. [PUBMED: 26680684] ">Scalzo 2015</a>; <a href="./references#CD012983-bbs2-0038" title="SerraJ . Chachacoma: An alternative treatment for the prevention of acute mountain sickness? [Chachacoma ¿un tratamiento alternativo para la prevención del mal agudo de montaña?]. Revista de Ciencias de la Salud2001;5(1):36‐42. [lil‐498122] ">Serra 2001</a>; <a href="./references#CD012983-bbs2-0039" title="SiebenmannC , BlochKE , LundbyC , Nussbamer‐OchsnerY , SchoebM , MaggioriniM . Dexamethasone improves maximal exercise capacity of individuals susceptible to high altitude pulmonary edema at 4559 m. High Altitude Medicine &amp; Biology2011;12(2):169‐77. [PUBMED: 21718165] ">Siebenmann 2011</a>; <a href="./references#CD012983-bbs2-0040" title="SinghI , KhannaPK , SrivastavaMC , LalM , RoySB , SubramanyamCS . Acute mountain sickness. New England Journal of Medicine1969;280(4):175‐84. [PUBMED: 5782719] ">Singh 1969</a>; <a href="./references#CD012983-bbs2-0041" title='SolísJV . Acetazolamide: Effects on the "acute mountain sickness", aggravated by physical activity. Boletín de la Fundación Jiménez Díaz1984;11(3):117‐20. '>Solís 1984</a>; <a href="./references#CD012983-bbs2-0042" title="SuhKS , KimT , YiNJ , HongG . Preparation for high altitude expedition and changes in cardiopulmonary and biochemical laboratory parameters with ascent to high altitude in transplant patients and live donors. Clinical Transplantation2015;29(11):1013‐20. [PUBMED: 26331794] ">Suh 2015</a>; <a href="./references#CD012983-bbs2-0043" title="TeppemaLJ , BalanosGM , SteinbackCD , BrownAD , FosterGE , DuffHJ , et al. Effects of acetazolamide on ventilatory, cerebrovascular, and pulmonary vascular responses to hypoxia. American Journal of Respiratory and Critical Care Medicine2007;175(3):277‐81. [PUBMED: 17095745] ">Teppema 2007</a>; <a href="./references#CD012983-bbs2-0044" title="VuykJ , Van DenBosJ , TerhellK , DeBosR , VletterA , ValkP , et al. Acetazolamide improves cerebral oxygenation during exercise at high altitude. High Altitude Medicine &amp; Biology2006;7(4):290‐301. [PUBMED: 17173514] ">Vuyk 2006</a>; <a href="./references#CD012983-bbs2-0045" title="WhiteAJ . Cognitive impairment of acute mountain sickness and acetazolamide. Aviation, Space, and Environmental Medicine1984;55(7):598‐603. [PUBMED: 6466255] ">White 1984</a>; <a href="./references#CD012983-bbs2-0046" title="WrightAD , BradwellAR , JensenJ , LassenN . Cerebral blood flow in acute mountain sickness and treatment with acetazolamide. Clinical Science1988;74 Suppl 18:1P. [DOI: 10.1042/cs074001P] ">Wright 1988</a>). Twenty‐eight (73.6%) out of the 38 studies were excluded because they did not focus on HAI prevention: instead they reported physiological or laboratory results related to altitude ascent. In eight of the excluded studies, the authors reported results for the treatment of HAI conditions (21%). The remaining references were excluded for other reasons. </p> <p>For further information refer to the table <a href="./references#CD012983-sec-0143" title="">Characteristics of excluded studies</a>. </p> <section id="CD012983-sec-0061"> <h5 class="title">Studies awaiting classification</h5> <p>We classified 12 studies as awaiting assessment (<a href="./references#CD012983-bbs2-0047" title="DugasL , DubrayC , HerryJP , OlsenNV , Court‐PayenM , HansenJM , et al. Cardiovascular effects of a calcium channel blocker in hypoxia caused by altitude [Effets cardiovasculaires d'un bloqueur calcique en hypoxie d'altitude.]. Presse Medicale1995;24(16):763‐8. [PUBMED: 7784415] ">Dugas 1995</a>; <a href="./references#CD012983-bbs2-0048" title="EllsworthAJ , LarsonEB , StricklandD . A randomized trial of dexamethasone and acetazolamide for acute mountain sickness prophylaxis. American Journal of Medicine1987;83(6):1024‐30. [PUBMED: 3332564] ">Ellsworth 1987</a>; <a href="./references#CD012983-bbs2-0049" title="FurianM , LichtblauM , AeschbacherSS , BisangM , HartmannSE , PoulinM , et al. Altitude related adverse health effects in lowlanders with COPD travelling to 3,200 m. randomized trial of preventive dexamethasone treatment. Respiration2016;91(5):415. ">Furian 2016</a>; <a href="./references#CD012983-bbs2-0050" title="HeftiJP , StutzM , GeiserT , HeftiU , MerzT , HuberA . Effect of antioxidant supplements on AMS and endothelial function during a high altitude expedition: A prospective randomized double‐blind trial. High Altitude Medicine &amp; Biology2014;15(2):A262. ">Hefti 2014</a>; <a href="./references#CD012983-bbs2-0051" title="KasicJF , YaronM , NicholasRA , LickteigJA , RoachR . Treatment of acute mountain‐sickness ‐ hyperbaric versus oxygen‐therapy. Annals of Emergency Medicine1991;20:1109‐12. ">Kasic 1991</a>; <a href="./references#CD012983-bbs2-0052" title="LeeJH , ChoiPC . Comparison of Methazolamide and Acetazolamide for Prevention of Acute Mountain Sickness in Adolescents. Journal of the Korean Society of Emergency Medicine2011;22(5):523‐30. ">Lee 2011</a>; <a href="./references#CD012983-bbs2-0053" title="PunM , NeupaneM , LohaniA , ThapaGB , YadavS , HolckPS , et al. Role of low‐dose acetazolamide (125 mg BID) in prevention of acute mountain sickness in pilgrims ascending rapidly: A prospective double‐blind placebo controlled randomized trial. High Altitude Medicine &amp; Biology2014;15(2):A233. ">Pun 2014</a>; <a href="./references#CD012983-bbs2-0054" title="RoncinJP , SchwartzF , DarbignyP . Egb 761 in control of acute mountain sickness and vascular reactivity to cold exposure. Aviation, Space, and Environmental Medicine1996;67(5):445‐52. ">Roncin 1996</a>; <a href="./references#CD012983-bbs2-0055" title="SwensonER , MacdonaldA , VatheuerM , MaksC , TreadwellA , AllenR , et al. Acute mountain sickness is not altered by a high carbohydrate diet nor associated with elevated circulating cytokines. Aviation, Space, and Environmental Medicine1997;68(6):499‐503. ">Swenson 1997</a>; <a href="./references#CD012983-bbs2-0056" title="UtzG , SchlierfG , BarthP , LinhartP , WollenweberJ . Prevention of acute mountain sickness using acetazolamide [Prophylaxe der akuten Hohenkrankheit mit Acetazolamid]. Munchener Medizinische Wochenschrift1970;112(23):1122‐4. [PUBMED: 5467747] ">Utz 1970</a>; <a href="./references#CD012983-bbs2-0057" title="WangW , ZhangX , MaY . Low‐concentration nitrous oxide inhalation in the treatment of high‐altitude pulmonary edema. [Chinese]. Chinese Journal of Tuberculosis and Respiratory Diseases1998;21:212‐4. ">Wang 1998</a>; <a href="./references#CD012983-bbs2-0058" title="XiangjunL , LanH . Inhaled budesonide for the prevention of acute mountain sickness in unacclimatization young men: A double‐blind randomized controlled trial. Journal of the American College of Cardiology2014;64(16 SUPPL. 1):C69. ">Xiangjun 2014</a>). This is because we were unable to obtain the full texts from the authors, the Anaesthesia, Critical and Emergency Care Group (ACE) or the Iberoamerican Cochrane Centre. For further information refer to the table <a href="./references#CD012983-sec-0144" title="">Characteristics of studies awaiting classification</a>. </p> </section> <section id="CD012983-sec-0062"> <h5 class="title">Ongoing studies</h5> <p>We considered an additional 12 studies as ongoing given that we were only able to find them cited in trial registers, but we considered that they could be due for publication shortly (<a href="./references#CD012983-bbs2-0059" title="ChiCTR‐TRC‐13003319 . Oral Zolpidem for Improving Sleep and then Prevention of Acute Mountain Sickness: A Single Center, Randomized, Double‐Blind, Controlled, Prospective Trial. [Oral Zolpidem for Improving Sleep and then Prevention of Acute Mountain Sickness]. apps.who.int/trialsearch/Trial2.aspx?TrialID=ChiCTR‐TRC‐13003319 (first received 29 June 2013). ">ChiCTR‐TRC‐13003319</a>; <a href="./references#CD012983-bbs2-0060" title="ChiCTR‐TRC‐13003590 . The meaning of intravenous iron supplementation In acute mountain sickness: a randomized, double‐blinded, placebo‐controlled trials. apps.who.int/trialsearch/Trial2.aspx?TrialID=ChiCTR‐TRC‐13003590 (first received 23 June 2013). ">ChiCTR‐TRC‐13003590</a>; <a href="./references#CD012983-bbs2-0061" title="NCT00886912 . Training in hypoxia to prevent acute mountain sickness [Prevention of acute mountain sickness (AMS) by intermittent hypoxic training]. apps.who.int/trialsearch/Trial2.aspx?TrialID=NCT00886912 (first received 21 April 2009). ">NCT00886912</a>; <a href="./references#CD012983-bbs2-0062" title="NCT01606527 . NSAID RCT for prevention of altitude sickness [Prospective, double‐blind, randomized, placebo‐controlled trial of ibuprofen versus placebo for prevention of neurologic forms of altitude sickness]. apps.who.int/trialsearch/Trial2.aspx?TrialID=NCT01606527 (first received 13 April 2012). ">NCT01606527</a>; <a href="./references#CD012983-bbs2-0063" title="NCT01682551 . Evaluation of the prevention and treatment effects of chinese medicine on high altitude illness. apps.who.int/trialsearch/Trial2.aspx?TrialID=NCT01682551 (first received 5 September 2012). ">NCT01682551</a>; <a href="./references#CD012983-bbs2-0064" title="NCT01794078 . A Study to test the safety of combined dosing with aminophylline and ambrisentan in exercising healthy human volunteers at simulated high altitude GQ02 [A randomized, 4‐sequence, double‐blind study to test the safety of combined dosing with aminophylline and ambrisentan in exercising healthy human volunteers at simulated high altitude]. apps.who.int/trialsearch/Trial2.aspx?TrialID=NCT01794078 (first received 10 February 2013). ">NCT01794078</a>; <a href="./references#CD012983-bbs2-0065" title="NCT01993667 . Acetazolamide for the prevention of high altitude illness: a comparison of dosing. http://apps.who.int/trialsearch/Trial2.aspx?TrialID=NCT01993667 (first received 12 November 2013). ">NCT01993667</a>; <a href="./references#CD012983-bbs2-0066" title="NCT02244437 . Ibuprofen vs acetaminophen for AMS prevention [Ibuprofen vs acetaminophen in the prevention of acute mountain sickness: a double blind, randomized controlled trial]. apps.who.int/trialsearch/Trial2.aspx?TrialID=NCT02244437 (first received 14 September 2014). ">NCT02244437</a>; <a href="./references#CD012983-bbs2-0067" title="NCT02450968 . Altitude related illness in patients with respiratory disease [Dexamethasone for prophylaxis of acute mountain sickness in patients with chronic obstructive pulmonary disease travelling to altitude]. http://apps.who.int/trialsearch/Trial2.aspx?TrialID=NCT02450968 (first received 18 May 2015). ">NCT02450968</a>; <a href="./references#CD012983-bbs2-0068" title="NCT02604173 . Altitude sickness prevention and Efficacy of Comparative Treatments ASPECT [A randomized controlled trial of altitude sickness prevention and efficacy of comparative treatments]. apps.who.int/trialsearch/Trial2.aspx?TrialID=NCT02604173 (first received 6 November 2015). ">NCT02604173</a>; <a href="./references#CD012983-bbs2-0069" title="NCT02811016 . Inhaled budesonide and acute mountain sickness [Effect of inhaled budesonide on the incidence and severity of acute mountain sickness at 4559 m]. apps.who.int/trialsearch/Trial2.aspx?TrialID=NCT02811016 (first received 14 June 2016). ">NCT02811016</a>; <a href="./references#CD012983-bbs2-0070" title="NCT02941510 . Inhaled Budesonide for Altitude Illness Prevention [Inhaled Budesonide for Altitude Illness Prevention]. apps.who.int/trialsearch/Trial2.aspx?TrialID=NCT02941510 (first received 19 October 2016). ">NCT02941510</a>). For further information refer to the table <a href="./references#CD012983-sec-0145" title="">Characteristics of ongoing studies</a>. </p> </section> </section> </section> <section id="CD012983-sec-0063"> <h3 class="title">Risk of bias in included studies</h3> <p>The risk of bias for the studies was assessed in seven categories. We provide a summary of our assessment of the methodological quality of included studies in <a href="#CD012983-fig-0002">Figure 2</a> and <a href="#CD012983-fig-0003">Figure 3</a>. </p> <div class="figure" id="CD012983-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD012983-fig-0002" src="/cdsr/doi/10.1002/14651858.CD012983/media/CDSR/CD012983/image_n/nCD012983-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> </div> <div class="figure" id="CD012983-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD012983-fig-0003" src="/cdsr/doi/10.1002/14651858.CD012983/media/CDSR/CD012983/image_n/nCD012983-AFig-FIG03.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> <section id="CD012983-sec-0064"> <h4 class="title">Allocation</h4> <p>In four studies, the authors reported a valid method of randomization (<a href="./references#CD012983-bbs2-0002" title="DumontL , LysakowskiC , TramerMR , JunodJD , MardirosoffC , TassonyiE , et al. Magnesium for the prevention and treatment of acute mountain sickness. Clinical Science2004;106(3):269‐77. [PUBMED: 14572305] LysakowskiC , VonElmE , DumontL , JunodJD , TassonyiE , KayserB , et al. Effect of magnesium, high altitude and acute mountain sickness on blood flow velocity in the middle cerebral artery. Clinical Science2004;106(3):279‐85. [PUBMED: 14572304] ">Dumont 2004</a>; <a href="./references#CD012983-bbs2-0003" title="JafarianS , GorouhiF , SalimiS , LotfiJ . Sumatriptan for prevention of acute mountain sickness: randomized clinical trial. Annals of Neurology2007;62(3):273‐7. [PUBMED: 17557349] ">Jafarian 2007</a>; <a href="./references#CD012983-bbs2-0004" title="JafarianS , AbolfazliR , GorouhiF , RezaieS , LotfiJ . Gabapentin for prevention of hypobaric hypoxia‐induced headache: randomized double‐blind clinical trial. Journal of Neurology, Neurosurgery, and Psychiatry2008;79(3):321‐3. [PUBMED: 17965148] ">Jafarian 2008</a>; <a href="./references#CD012983-bbs2-0005" title="JainSC , SinghMV , SharmaVM , RawalSB , TyagiAK . Amelioration of acute mountain sickness: comparative study of acetazolamide and spironolactone. International Journal of Biometeorology1986;30(4):293‐300. [PUBMED: 3804482] ">Jain 1986</a>), whereas this information was not clearly reported in the remaining studies (50%). Similarly, only two studies undertook and reported random allocation concealment (<a href="./references#CD012983-bbs2-0003" title="JafarianS , GorouhiF , SalimiS , LotfiJ . Sumatriptan for prevention of acute mountain sickness: randomized clinical trial. Annals of Neurology2007;62(3):273‐7. [PUBMED: 17557349] ">Jafarian 2007</a>; <a href="./references#CD012983-bbs2-0004" title="JafarianS , AbolfazliR , GorouhiF , RezaieS , LotfiJ . Gabapentin for prevention of hypobaric hypoxia‐induced headache: randomized double‐blind clinical trial. Journal of Neurology, Neurosurgery, and Psychiatry2008;79(3):321‐3. [PUBMED: 17965148] ">Jafarian 2008</a>), and the information was absent in the remaining included studies (75%). </p> </section> <section id="CD012983-sec-0065"> <h4 class="title">Blinding</h4> <p>Four studies reported adequate blinding of participants and personnel (<a href="./references#CD012983-bbs2-0001" title="BrookfieldDS , ListonWA , BrownGV . Use of spironolactone in the prevention of acute mountain sickness on Kilimanjaro. East African Medical Journal1977;54(12):689‐91. [PUBMED: 612430] ">Brookfield 1977</a>; <a href="./references#CD012983-bbs2-0002" title="DumontL , LysakowskiC , TramerMR , JunodJD , MardirosoffC , TassonyiE , et al. Magnesium for the prevention and treatment of acute mountain sickness. Clinical Science2004;106(3):269‐77. [PUBMED: 14572305] LysakowskiC , VonElmE , DumontL , JunodJD , TassonyiE , KayserB , et al. Effect of magnesium, high altitude and acute mountain sickness on blood flow velocity in the middle cerebral artery. Clinical Science2004;106(3):279‐85. [PUBMED: 14572304] ">Dumont 2004</a>; <a href="./references#CD012983-bbs2-0003" title="JafarianS , GorouhiF , SalimiS , LotfiJ . Sumatriptan for prevention of acute mountain sickness: randomized clinical trial. Annals of Neurology2007;62(3):273‐7. [PUBMED: 17557349] ">Jafarian 2007</a>; <a href="./references#CD012983-bbs2-0004" title="JafarianS , AbolfazliR , GorouhiF , RezaieS , LotfiJ . Gabapentin for prevention of hypobaric hypoxia‐induced headache: randomized double‐blind clinical trial. Journal of Neurology, Neurosurgery, and Psychiatry2008;79(3):321‐3. [PUBMED: 17965148] ">Jafarian 2008</a>). In the remaining four studies, this domain was classified as unclear (<a href="./references#CD012983-bbs2-0005" title="JainSC , SinghMV , SharmaVM , RawalSB , TyagiAK . Amelioration of acute mountain sickness: comparative study of acetazolamide and spironolactone. International Journal of Biometeorology1986;30(4):293‐300. [PUBMED: 3804482] ">Jain 1986</a>; <a href="./references#CD012983-bbs2-0006" title="LarsenRF , RockPB , FulcoCS , EdelmanB , YoungAJ , CymermanA . Effect of spironolactone on acute mountain sickness. Aviation, Space, and Environmental Medicine1986;57(6):543‐7. [PUBMED: 3718378] ">Larsen 1986</a>; <a href="./references#CD012983-bbs2-0007" title="BasnyatB , HolckPS , PunM , HalversonS , SzawarskiP , GertschJ , et al. Spironolactone does not prevent acute mountain sickness: a prospective, double‐blind, randomized, placebo‐controlled trial by SPACE Trial Group (spironolactone and acetazolamide trial in the prevention of acute mountain sickness group). Wilderness &amp; Environmental Medicine2011;22(1):15‐22. [PUBMED: 21377114] ">SPACE 2011</a>; <a href="./references#CD012983-bbs2-0008" title="WohnsRN , ColpittsM , ClementT , KaruzaA , BlackettWB , FoutchR , et al. Phenytoin and acute mountain sickness on Mount Everest. American Journal of Medicine1986;80(1):32‐6. [PUBMED: 3510539] ">Wohns 1986</a>). </p> <p>Regarding detection bias, the risk was considered as low in only three studies (<a href="./references#CD012983-bbs2-0002" title="DumontL , LysakowskiC , TramerMR , JunodJD , MardirosoffC , TassonyiE , et al. Magnesium for the prevention and treatment of acute mountain sickness. Clinical Science2004;106(3):269‐77. [PUBMED: 14572305] LysakowskiC , VonElmE , DumontL , JunodJD , TassonyiE , KayserB , et al. Effect of magnesium, high altitude and acute mountain sickness on blood flow velocity in the middle cerebral artery. Clinical Science2004;106(3):279‐85. [PUBMED: 14572304] ">Dumont 2004</a>; <a href="./references#CD012983-bbs2-0003" title="JafarianS , GorouhiF , SalimiS , LotfiJ . Sumatriptan for prevention of acute mountain sickness: randomized clinical trial. Annals of Neurology2007;62(3):273‐7. [PUBMED: 17557349] ">Jafarian 2007</a>; <a href="./references#CD012983-bbs2-0004" title="JafarianS , AbolfazliR , GorouhiF , RezaieS , LotfiJ . Gabapentin for prevention of hypobaric hypoxia‐induced headache: randomized double‐blind clinical trial. Journal of Neurology, Neurosurgery, and Psychiatry2008;79(3):321‐3. [PUBMED: 17965148] ">Jafarian 2008</a>), whereas this information was considered as unclear in the remaining studies (62%). In three of the studies, the risk of bias was classified as low for both blindings (<a href="./references#CD012983-bbs2-0002" title="DumontL , LysakowskiC , TramerMR , JunodJD , MardirosoffC , TassonyiE , et al. Magnesium for the prevention and treatment of acute mountain sickness. Clinical Science2004;106(3):269‐77. [PUBMED: 14572305] LysakowskiC , VonElmE , DumontL , JunodJD , TassonyiE , KayserB , et al. Effect of magnesium, high altitude and acute mountain sickness on blood flow velocity in the middle cerebral artery. Clinical Science2004;106(3):279‐85. [PUBMED: 14572304] ">Dumont 2004</a>; <a href="./references#CD012983-bbs2-0003" title="JafarianS , GorouhiF , SalimiS , LotfiJ . Sumatriptan for prevention of acute mountain sickness: randomized clinical trial. Annals of Neurology2007;62(3):273‐7. [PUBMED: 17557349] ">Jafarian 2007</a>; <a href="./references#CD012983-bbs2-0004" title="JafarianS , AbolfazliR , GorouhiF , RezaieS , LotfiJ . Gabapentin for prevention of hypobaric hypoxia‐induced headache: randomized double‐blind clinical trial. Journal of Neurology, Neurosurgery, and Psychiatry2008;79(3):321‐3. [PUBMED: 17965148] ">Jafarian 2008</a>). </p> </section> <section id="CD012983-sec-0066"> <h4 class="title">Incomplete outcome data</h4> <p>Significant numbers of participants were lost or excluded from the final analysis of one study (<a href="./references#CD012983-bbs2-0001" title="BrookfieldDS , ListonWA , BrownGV . Use of spironolactone in the prevention of acute mountain sickness on Kilimanjaro. East African Medical Journal1977;54(12):689‐91. [PUBMED: 612430] ">Brookfield 1977</a>). Two further studies presented unclear data (<a href="./references#CD012983-bbs2-0004" title="JafarianS , AbolfazliR , GorouhiF , RezaieS , LotfiJ . Gabapentin for prevention of hypobaric hypoxia‐induced headache: randomized double‐blind clinical trial. Journal of Neurology, Neurosurgery, and Psychiatry2008;79(3):321‐3. [PUBMED: 17965148] ">Jafarian 2008</a>; <a href="./references#CD012983-bbs2-0005" title="JainSC , SinghMV , SharmaVM , RawalSB , TyagiAK . Amelioration of acute mountain sickness: comparative study of acetazolamide and spironolactone. International Journal of Biometeorology1986;30(4):293‐300. [PUBMED: 3804482] ">Jain 1986</a>). In the remaining five studies, the risk of bias was classified as low (62.5%). </p> </section> <section id="CD012983-sec-0067"> <h4 class="title">Selective reporting</h4> <p>Reporting adverse events associated with the different types of interventions is fundamental for the complete assessment of their usefulness in clinical practice. We found that all studies bar one did not report other adverse events associated with the classes of drugs commonly used for prevention of AMS (such as paraesthesia: <a href="./references#CD012983-bbs2-0001" title="BrookfieldDS , ListonWA , BrownGV . Use of spironolactone in the prevention of acute mountain sickness on Kilimanjaro. East African Medical Journal1977;54(12):689‐91. [PUBMED: 612430] ">Brookfield 1977</a>; <a href="./references#CD012983-bbs2-0002" title="DumontL , LysakowskiC , TramerMR , JunodJD , MardirosoffC , TassonyiE , et al. Magnesium for the prevention and treatment of acute mountain sickness. Clinical Science2004;106(3):269‐77. [PUBMED: 14572305] LysakowskiC , VonElmE , DumontL , JunodJD , TassonyiE , KayserB , et al. Effect of magnesium, high altitude and acute mountain sickness on blood flow velocity in the middle cerebral artery. Clinical Science2004;106(3):279‐85. [PUBMED: 14572304] ">Dumont 2004</a>; <a href="./references#CD012983-bbs2-0005" title="JainSC , SinghMV , SharmaVM , RawalSB , TyagiAK . Amelioration of acute mountain sickness: comparative study of acetazolamide and spironolactone. International Journal of Biometeorology1986;30(4):293‐300. [PUBMED: 3804482] ">Jain 1986</a>; <a href="./references#CD012983-bbs2-0006" title="LarsenRF , RockPB , FulcoCS , EdelmanB , YoungAJ , CymermanA . Effect of spironolactone on acute mountain sickness. Aviation, Space, and Environmental Medicine1986;57(6):543‐7. [PUBMED: 3718378] ">Larsen 1986</a>; <a href="./references#CD012983-bbs2-0007" title="BasnyatB , HolckPS , PunM , HalversonS , SzawarskiP , GertschJ , et al. Spironolactone does not prevent acute mountain sickness: a prospective, double‐blind, randomized, placebo‐controlled trial by SPACE Trial Group (spironolactone and acetazolamide trial in the prevention of acute mountain sickness group). Wilderness &amp; Environmental Medicine2011;22(1):15‐22. [PUBMED: 21377114] ">SPACE 2011</a>; <a href="./references#CD012983-bbs2-0008" title="WohnsRN , ColpittsM , ClementT , KaruzaA , BlackettWB , FoutchR , et al. Phenytoin and acute mountain sickness on Mount Everest. American Journal of Medicine1986;80(1):32‐6. [PUBMED: 3510539] ">Wohns 1986</a>); and <a href="./references#CD012983-bbs2-0004" title="JafarianS , AbolfazliR , GorouhiF , RezaieS , LotfiJ . Gabapentin for prevention of hypobaric hypoxia‐induced headache: randomized double‐blind clinical trial. Journal of Neurology, Neurosurgery, and Psychiatry2008;79(3):321‐3. [PUBMED: 17965148] ">Jafarian 2008</a> reported unclear information for side effects. </p> </section> <section id="CD012983-sec-0068"> <h4 class="title">Other potential sources of bias</h4> <p>We found an unclear source of bias in <a href="./references#CD012983-bbs2-0006" title="LarsenRF , RockPB , FulcoCS , EdelmanB , YoungAJ , CymermanA . Effect of spironolactone on acute mountain sickness. Aviation, Space, and Environmental Medicine1986;57(6):543‐7. [PUBMED: 3718378] ">Larsen 1986</a>, because it is unclear whether previous events of HAI (specifically in phase 1) affects the probability of new events in the second phase of cross‐over trials. We identified no additional sources of risk in the remaining studies. </p> </section> </section> <section id="CD012983-sec-0069"> <h3 class="title" id="CD012983-sec-0069">Effects of interventions</h3> <p>See: <a href="./full#CD012983-tbl-0001"><b>Summary of findings for the main comparison</b> Sumatriptan compared with placebo for preventing high altitude illness</a>; <a href="./full#CD012983-tbl-0002"><b>Summary of findings 2</b> Magnesium citrate compared with placebo for preventing high altitude illness</a>; <a href="./full#CD012983-tbl-0003"><b>Summary of findings 3</b> Spironolactone compared with placebo for preventing high altitude illness</a>; <a href="./full#CD012983-tbl-0004"><b>Summary of findings 4</b> Acetazolamide compared with spironolactone for preventing high altitude illness</a> </p> <p>See <a href="./full#CD012983-tbl-0001">summary of findings Table for the main comparison</a>; <a href="./full#CD012983-tbl-0002">summary of findings Table 2</a>; <a href="./full#CD012983-tbl-0003">summary of findings Table 3</a>; <a href="./full#CD012983-tbl-0004">summary of findings Table 4</a> </p> <section id="CD012983-sec-0070"> <h4 class="title">Comparison 1: selective 5‐hydroxytryptamine(1) receptor agonist: sumatriptan versus placebo </h4> <p>For this comparison, we analysed the information from one study (<a href="./references#CD012983-bbs2-0003" title="JafarianS , GorouhiF , SalimiS , LotfiJ . Sumatriptan for prevention of acute mountain sickness: randomized clinical trial. Annals of Neurology2007;62(3):273‐7. [PUBMED: 17557349] ">Jafarian 2007</a>), with a total of 102 participants. The dosage used was 50 mg/day, and the study was developed in Iran, reaching a maximum altitude of 3500 metres. </p> <section id="CD012983-sec-0071"> <h5 class="title">Primary outcome 1: risk of acute mountain sickness (AMS)</h5> <p><a href="./references#CD012983-bbs2-0003" title="JafarianS , GorouhiF , SalimiS , LotfiJ . Sumatriptan for prevention of acute mountain sickness: randomized clinical trial. Annals of Neurology2007;62(3):273‐7. [PUBMED: 17557349] ">Jafarian 2007</a> provided information about the risk of AMS, with a total of 30 events (9/51 (17.6%) in the sumatriptan group versus 21/51 (41.1%) taking the placebo). AMS was defined as a Lake Louise AMS score of 3 or higher, with headache. The estimated RR for AMS, comparing sumatriptan versus placebo, was 0.43 (95% CI 0.21 to 0.84; 102 participants). We downgraded the quality of evidence from high to low due to imprecision issues (See <a href="./full#CD012983-tbl-0001">summary of findings Table for the main comparison</a>). </p> </section> <section id="CD012983-sec-0072"> <h5 class="title">Secondary outcome 1: risk of high altitude pulmonary oedema (HAPE)</h5> <p>We found no information about this outcome in the included study.</p> </section> <section id="CD012983-sec-0073"> <h5 class="title">Secondary outcome 2: risk of high altitude cerebral oedema (HACE)</h5> <p>We found no information about this outcome in the included study.</p> </section> <section id="CD012983-sec-0074"> <h5 class="title">Secondary outcome 3: risk of adverse events</h5> <p>We found no information about this outcome in the included study.</p> </section> <section id="CD012983-sec-0075"> <h5 class="title">Secondary outcome 4: differences in HAI/AMS scores</h5> <p><a href="./references#CD012983-bbs2-0003" title="JafarianS , GorouhiF , SalimiS , LotfiJ . Sumatriptan for prevention of acute mountain sickness: randomized clinical trial. Annals of Neurology2007;62(3):273‐7. [PUBMED: 17557349] ">Jafarian 2007</a> reported a lower Lake Louise AMS score in the sumatriptan group (51 participants; median = 3, IQR = 3) than placebo group (51 participants; median = 1.5, IQR = 2.75; P = 0.005). We were unable to transform this information to means and standard deviations. </p> </section> </section> <section id="CD012983-sec-0076"> <h4 class="title">Comparison 2: N‐methyl‐D‐aspartate (NMDA) antagonist: magnesium citrate versus placebo</h4> <p>For this comparison we analysed the information from one study (<a href="./references#CD012983-bbs2-0002" title="DumontL , LysakowskiC , TramerMR , JunodJD , MardirosoffC , TassonyiE , et al. Magnesium for the prevention and treatment of acute mountain sickness. Clinical Science2004;106(3):269‐77. [PUBMED: 14572305] LysakowskiC , VonElmE , DumontL , JunodJD , TassonyiE , KayserB , et al. Effect of magnesium, high altitude and acute mountain sickness on blood flow velocity in the middle cerebral artery. Clinical Science2004;106(3):279‐85. [PUBMED: 14572304] ">Dumont 2004</a>), with a total of 70 participants. The dose used was 1200 mg/day, and the study was planned in Switzerland, and undertaken in Italy, reaching a maximum altitude of 4559 metres. There were 20 participants with a history of AMS (10 in each group). </p> <section id="CD012983-sec-0077"> <h5 class="title">Primary outcome 1: risk of acute mountain sickness (AMS)</h5> <p><a href="./references#CD012983-bbs2-0002" title="DumontL , LysakowskiC , TramerMR , JunodJD , MardirosoffC , TassonyiE , et al. Magnesium for the prevention and treatment of acute mountain sickness. Clinical Science2004;106(3):269‐77. [PUBMED: 14572305] LysakowskiC , VonElmE , DumontL , JunodJD , TassonyiE , KayserB , et al. Effect of magnesium, high altitude and acute mountain sickness on blood flow velocity in the middle cerebral artery. Clinical Science2004;106(3):279‐85. [PUBMED: 14572304] ">Dumont 2004</a> provided information about the risk of acute mountain sickness and found a total of 23 events (12/35 (34.2%) of those taking magnesium versus 11/35 (31.4%) of those taking placebo). AMS was defined as a Lake Louise AMS score greater than 6 with headache score greater than 2 and gastrointestinal/ataxias score greater than 2. The estimated RR for AMS, comparing magnesium citrate tablets versus placebo, was 1.09 (95% CI 0.55 to 2.13; 70 participants). We downgraded the quality of evidence from high to low due to imprecision issues (See <a href="./full#CD012983-tbl-0002">summary of findings Table 2</a>). </p> </section> <section id="CD012983-sec-0078"> <h5 class="title">Secondary outcome 1: risk of high altitude pulmonary oedema (HAPE)</h5> <p>We found no information about this outcome in the included study.</p> </section> <section id="CD012983-sec-0079"> <h5 class="title">Secondary outcome 2: risk of high altitude cerebral oedema (HACE)</h5> <p>We found no information about this outcome in the included study.</p> </section> <section id="CD012983-sec-0080"> <h5 class="title">Secondary outcome 3: risk of adverse events</h5> <p><a href="./references#CD012983-bbs2-0002" title="DumontL , LysakowskiC , TramerMR , JunodJD , MardirosoffC , TassonyiE , et al. Magnesium for the prevention and treatment of acute mountain sickness. Clinical Science2004;106(3):269‐77. [PUBMED: 14572305] LysakowskiC , VonElmE , DumontL , JunodJD , TassonyiE , KayserB , et al. Effect of magnesium, high altitude and acute mountain sickness on blood flow velocity in the middle cerebral artery. Clinical Science2004;106(3):279‐85. [PUBMED: 14572304] ">Dumont 2004</a> provided information about the risk of loose stools and they found a total of 17 events (13/35 (37.1%) in those taking magnesium versus 4/35 (11.4%) of those taking placebo). The estimated RR for this adverse event, comparing magnesium citrate versus placebo, was 3.25 (95% CI 1.17 to 8.99; 70 participants). We downgraded the quality of evidence from high to moderate due to imprecision (see <a href="./full#CD012983-tbl-0002">summary of findings Table 2</a>). </p> </section> <section id="CD012983-sec-0081"> <h5 class="title">Secondary outcome 4: differences in HAI/AMS scores</h5> <p>We found no information about this outcome in the included study.</p> </section> </section> <section id="CD012983-sec-0082"> <h4 class="title">Comparison 3: endothelin‐1 antagonist — bosentan versus placebo</h4> <p>We did not find trials which evaluate the role of bosentan in prevention of HAI conditions.</p> </section> <section id="CD012983-sec-0083"> <h4 class="title">Comparison 4: Anticonvulsant drugs — phenytoin versus placebo</h4> <p>For this comparison, we identified one study with a total of 21 participants (<a href="./references#CD012983-bbs2-0008" title="WohnsRN , ColpittsM , ClementT , KaruzaA , BlackettWB , FoutchR , et al. Phenytoin and acute mountain sickness on Mount Everest. American Journal of Medicine1986;80(1):32‐6. [PUBMED: 3510539] ">Wohns 1986</a>). However this study did not provide information about any of the outcomes selected for this review. This study was planned in the USA and undertaken in Nepal, reaching a maximum altitude of 5120 metres. All the participants in this study were climbers. </p> </section> <section id="CD012983-sec-0084"> <h4 class="title">Comparison 5: Spironolactone versus placebo</h4> <p>For this comparison, we analysed the information from two studies with a total of 205 participants (<a href="./references#CD012983-bbs2-0001" title="BrookfieldDS , ListonWA , BrownGV . Use of spironolactone in the prevention of acute mountain sickness on Kilimanjaro. East African Medical Journal1977;54(12):689‐91. [PUBMED: 612430] ">Brookfield 1977</a>; <a href="./references#CD012983-bbs2-0007" title="BasnyatB , HolckPS , PunM , HalversonS , SzawarskiP , GertschJ , et al. Spironolactone does not prevent acute mountain sickness: a prospective, double‐blind, randomized, placebo‐controlled trial by SPACE Trial Group (spironolactone and acetazolamide trial in the prevention of acute mountain sickness group). Wilderness &amp; Environmental Medicine2011;22(1):15‐22. [PUBMED: 21377114] ">SPACE 2011</a>). Investigators administered 75 mg/day in <a href="./references#CD012983-bbs2-0001" title="BrookfieldDS , ListonWA , BrownGV . Use of spironolactone in the prevention of acute mountain sickness on Kilimanjaro. East African Medical Journal1977;54(12):689‐91. [PUBMED: 612430] ">Brookfield 1977</a> and 100 mg/day in <a href="./references#CD012983-bbs2-0007" title="BasnyatB , HolckPS , PunM , HalversonS , SzawarskiP , GertschJ , et al. Spironolactone does not prevent acute mountain sickness: a prospective, double‐blind, randomized, placebo‐controlled trial by SPACE Trial Group (spironolactone and acetazolamide trial in the prevention of acute mountain sickness group). Wilderness &amp; Environmental Medicine2011;22(1):15‐22. [PUBMED: 21377114] ">SPACE 2011</a>. The studies were planned in the USA and Nepal and undertaken in Tanzania and Nepal, reaching a maximum altitude of 5898 and 5000 metres respectively. We also included one cross‐over study (<a href="./references#CD012983-bbs2-0006" title="LarsenRF , RockPB , FulcoCS , EdelmanB , YoungAJ , CymermanA . Effect of spironolactone on acute mountain sickness. Aviation, Space, and Environmental Medicine1986;57(6):543‐7. [PUBMED: 3718378] ">Larsen 1986</a>), with a total of 12 participants. However, this study did not provide information about any of the outcomes assessed in this review and did not contribute to any analysis. </p> <section id="CD012983-sec-0085"> <h5 class="title">Primary outcome 1: risk of acute mountain sickness (AMS)</h5> <p>Two studies provided information about the risk of acute mountain sickness (<a href="./references#CD012983-bbs2-0001" title="BrookfieldDS , ListonWA , BrownGV . Use of spironolactone in the prevention of acute mountain sickness on Kilimanjaro. East African Medical Journal1977;54(12):689‐91. [PUBMED: 612430] ">Brookfield 1977</a>; <a href="./references#CD012983-bbs2-0007" title="BasnyatB , HolckPS , PunM , HalversonS , SzawarskiP , GertschJ , et al. Spironolactone does not prevent acute mountain sickness: a prospective, double‐blind, randomized, placebo‐controlled trial by SPACE Trial Group (spironolactone and acetazolamide trial in the prevention of acute mountain sickness group). Wilderness &amp; Environmental Medicine2011;22(1):15‐22. [PUBMED: 21377114] ">SPACE 2011</a>). A pooled analysis had an I² of 72% and this could not be explained by any of our planned subgroup analyses. We have therefore not pooled the results of these trials. <a href="./references#CD012983-bbs2-0001" title="BrookfieldDS , ListonWA , BrownGV . Use of spironolactone in the prevention of acute mountain sickness on Kilimanjaro. East African Medical Journal1977;54(12):689‐91. [PUBMED: 612430] ">Brookfield 1977</a> defined AMS as a clinical score (not defined) equal to or greater than 2 and reported AMS in 2/6 (33%) of participants taking spironolactone versus 5/6 (83%) of those taking placebo, RR 0.40 (95% CI 0.12 to 1.31). <a href="./references#CD012983-bbs2-0007" title="BasnyatB , HolckPS , PunM , HalversonS , SzawarskiP , GertschJ , et al. Spironolactone does not prevent acute mountain sickness: a prospective, double‐blind, randomized, placebo‐controlled trial by SPACE Trial Group (spironolactone and acetazolamide trial in the prevention of acute mountain sickness group). Wilderness &amp; Environmental Medicine2011;22(1):15‐22. [PUBMED: 21377114] ">SPACE 2011</a> defined AMS as a Lake Louise AMS score of headache and one additional symptom and reported AMS in 27/114 (23.6%) in those taking spironolactone versus 13/79 (16.5%) of those taking placebo, RR 1.44 (95% CI 0.79 to 2.01). These studies differ in terms of final altitude reached (5895 m versus 5000 m, respectively). We downgraded the quality of evidence from high to very low due to study limitations suggesting there may be a high risk of bias, inconsistency and imprecision with these two studies; (see <a href="./full#CD012983-tbl-0003">summary of findings Table 3</a>). We were unable to perform TSA due to high heterogeneity for this comparison. </p> </section> <section id="CD012983-sec-0086"> <h5 class="title">Secondary outcome 1: risk of high altitude pulmonary oedema (HAPE)</h5> <p><a href="./references#CD012983-bbs2-0007" title="BasnyatB , HolckPS , PunM , HalversonS , SzawarskiP , GertschJ , et al. Spironolactone does not prevent acute mountain sickness: a prospective, double‐blind, randomized, placebo‐controlled trial by SPACE Trial Group (spironolactone and acetazolamide trial in the prevention of acute mountain sickness group). Wilderness &amp; Environmental Medicine2011;22(1):15‐22. [PUBMED: 21377114] ">SPACE 2011</a> researchers assessed the risk of altitude pulmonary oedema, but they did not find events to report (Table 1). We downgraded the quality of evidence from high to low due to unclear risk of selection, performance and detection bias, as well as imprecision issues (See <a href="./full#CD012983-tbl-0003">summary of findings Table 3</a>). </p> </section> <section id="CD012983-sec-0087"> <h5 class="title">Secondary outcome 2: risk of high altitude cerebral oedema (HACE)</h5> <p><a href="./references#CD012983-bbs2-0007" title="BasnyatB , HolckPS , PunM , HalversonS , SzawarskiP , GertschJ , et al. Spironolactone does not prevent acute mountain sickness: a prospective, double‐blind, randomized, placebo‐controlled trial by SPACE Trial Group (spironolactone and acetazolamide trial in the prevention of acute mountain sickness group). Wilderness &amp; Environmental Medicine2011;22(1):15‐22. [PUBMED: 21377114] ">SPACE 2011</a> researchers assessed the risk of altitude cerebral oedema, but they did not find events to report (Table 1). We downgraded the quality of evidence from high to low due to unclear risk of selection, performance and detection bias, as well as imprecision issues (See <a href="./full#CD012983-tbl-0003">summary of findings Table 3</a>). </p> </section> <section id="CD012983-sec-0088"> <h5 class="title">Secondary outcome 3: risk of adverse events</h5> <p>We found no information about this outcome in the included study.</p> </section> <section id="CD012983-sec-0089"> <h5 class="title">Secondary outcome 4: differences in HAI/AMS scores</h5> <p>We found no information about this outcome in the included study</p> </section> </section> <section id="CD012983-sec-0090"> <h4 class="title">Comparison 6: other comparisons — acetazolamide versus spironolactone</h4> <p>Two studies reported this comparison, enrolling a total of 251 participants. They were conducted in India and Nepal, reaching a final altitude of 3000 and 5000 metres respectively (<a href="./references#CD012983-bbs2-0005" title="JainSC , SinghMV , SharmaVM , RawalSB , TyagiAK . Amelioration of acute mountain sickness: comparative study of acetazolamide and spironolactone. International Journal of Biometeorology1986;30(4):293‐300. [PUBMED: 3804482] ">Jain 1986</a>; <a href="./references#CD012983-bbs2-0007" title="BasnyatB , HolckPS , PunM , HalversonS , SzawarskiP , GertschJ , et al. Spironolactone does not prevent acute mountain sickness: a prospective, double‐blind, randomized, placebo‐controlled trial by SPACE Trial Group (spironolactone and acetazolamide trial in the prevention of acute mountain sickness group). Wilderness &amp; Environmental Medicine2011;22(1):15‐22. [PUBMED: 21377114] ">SPACE 2011</a>). No primary or secondary outcomes were reported by <a href="./references#CD012983-bbs2-0005" title="JainSC , SinghMV , SharmaVM , RawalSB , TyagiAK . Amelioration of acute mountain sickness: comparative study of acetazolamide and spironolactone. International Journal of Biometeorology1986;30(4):293‐300. [PUBMED: 3804482] ">Jain 1986</a>, so only <a href="./references#CD012983-bbs2-0007" title="BasnyatB , HolckPS , PunM , HalversonS , SzawarskiP , GertschJ , et al. Spironolactone does not prevent acute mountain sickness: a prospective, double‐blind, randomized, placebo‐controlled trial by SPACE Trial Group (spironolactone and acetazolamide trial in the prevention of acute mountain sickness group). Wilderness &amp; Environmental Medicine2011;22(1):15‐22. [PUBMED: 21377114] ">SPACE 2011</a> could contribute data to this review. This trial administered 500 mg of acetazolamide/day and 100 mg of spironolactone/day. </p> <section id="CD012983-sec-0091"> <h5 class="title">Primary outcome 1: risk of acute mountain sickness (AMS)</h5> <p><a href="./references#CD012983-bbs2-0007" title="BasnyatB , HolckPS , PunM , HalversonS , SzawarskiP , GertschJ , et al. Spironolactone does not prevent acute mountain sickness: a prospective, double‐blind, randomized, placebo‐controlled trial by SPACE Trial Group (spironolactone and acetazolamide trial in the prevention of acute mountain sickness group). Wilderness &amp; Environmental Medicine2011;22(1):15‐22. [PUBMED: 21377114] ">SPACE 2011</a> researchers found 37 events of acute mountain sickness for this comparison (10/118 (8.4%) of those taking actetazolamide versus 27/114 (23.6%) taking spironolactone. The estimated RR for AMS, comparing acetazolamide versus spironolactone, was 0.36 (95% CI 0.18 to 0.70); 232 participants). We downgraded the quality of evidence from high to low due to unclear risk of selection, performance and detection bias, as well as imprecision (See <a href="./full#CD012983-tbl-0004">summary of findings Table 4</a>). </p> </section> <section id="CD012983-sec-0092"> <h5 class="title">Secondary outcome 1: risk of high altitude pulmonary oedema (HAPE)</h5> <p>The authors of <a href="./references#CD012983-bbs2-0007" title="BasnyatB , HolckPS , PunM , HalversonS , SzawarskiP , GertschJ , et al. Spironolactone does not prevent acute mountain sickness: a prospective, double‐blind, randomized, placebo‐controlled trial by SPACE Trial Group (spironolactone and acetazolamide trial in the prevention of acute mountain sickness group). Wilderness &amp; Environmental Medicine2011;22(1):15‐22. [PUBMED: 21377114] ">SPACE 2011</a> did not find any events of high altitude pulmonary oedema. We downgraded the quality of evidence from high to low due to unclear risk of selection, performance and detection bias, as well as imprecision (See <a href="./full#CD012983-tbl-0004">summary of findings Table 4</a>). </p> </section> <section id="CD012983-sec-0093"> <h5 class="title">Secondary outcome 2: risk of high altitude cerebral oedema (HACE)</h5> <p>The authors of <a href="./references#CD012983-bbs2-0007" title="BasnyatB , HolckPS , PunM , HalversonS , SzawarskiP , GertschJ , et al. Spironolactone does not prevent acute mountain sickness: a prospective, double‐blind, randomized, placebo‐controlled trial by SPACE Trial Group (spironolactone and acetazolamide trial in the prevention of acute mountain sickness group). Wilderness &amp; Environmental Medicine2011;22(1):15‐22. [PUBMED: 21377114] ">SPACE 2011</a> did not find any events of high altitude cerebral oedema . We downgraded the quality of evidence from high to low due to unclear risk of selection, performance and detection bias, as well as imprecision (See <a href="./full#CD012983-tbl-0004">summary of findings Table 4</a>). </p> </section> <section id="CD012983-sec-0094"> <h5 class="title">Secondary outcome 3: risk of adverse events</h5> <p>We found no information about this outcome in the one included study.</p> </section> <section id="CD012983-sec-0095"> <h5 class="title">Secondary outcome 4: differences in HAI/AMS scores</h5> <p>We found no information about this outcome in the one included study.</p> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD012983-sec-0096" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD012983-sec-0096"></div> <section id="CD012983-sec-0097"> <h3 class="title" id="CD012983-sec-0097">Summary of main results</h3> <p>Evidence from eight studies and 334 participants showed the scarcity of evidence regarding the following five less commonly used classes of drugs for prevention of HAI conditions: selective 5‐hydroxytryptamine(1) receptor agonists; N‐methyl‐D‐aspartate (NMDA) antagonist; endothelin‐1 antagonist; anticonvulsant drugs; and spironolactone. For most of the assessed comparisons, we only found evidence from a single study. Four studies were at a low risk of bias for randomization, two for allocation concealment. Four studies were at a low risk of bias for blinding of participants and personnel. Three studies were considered at a low risk of bias for blinding of outcome assessors. Most studies were considered at high risk of selective reporting bias. </p> <p>We report results for the four main comparisons as follows.</p> <section id="CD012983-sec-0098"> <h4 class="title">Sumatriptan versus placebo (1 parallel study; 102 participants)</h4> <p>Data on sumatriptan showed a reduction of the risk of AMS when compared with a placebo (risk ratio (RR) 0.43 (95% CI 0.21 to 0.84); 1 study; 102 participants; low quality of evidence). This study did not report events of HAPE, HACE or adverse events related to administrations of sumatriptan. </p> </section> <section id="CD012983-sec-0099"> <h4 class="title">Magnesium citrate versus placebo (1 parallel study; 70 participants)</h4> <p>The estimated RR for AMS, comparing magnesium citrate tablets versus placebo, was 1.09 (95% CI 0.55 to 2.13; 1 study; 70 participants; low quality of evidence). In addition, the estimated RR for loose stools was 3.25 (95% CI 1.17 to 8.99; 1 study; 70 participants; low quality of evidence). The included study did not report events of HAPE or HACE. </p> </section> <section id="CD012983-sec-0100"> <h4 class="title">Spironolactone versus placebo (2 parallel studies; 205 participants)</h4> <p>Pooled estimation of RR for AMS was not performed due to considerable heterogeneity between included studies (I² = 72%). RR from individual studies was 0.40 (95% CI 0.12 to 1.31) and 1.44 (95% CI 0.79 to 2.01; very low quality of evidence). No events of HAPE or HACE were reported. Adverse events were not evaluated. </p> </section> <section id="CD012983-sec-0101"> <h4 class="title">Acetazolamide versus spironolactone (1 parallel study; 232 participants)</h4> <p>Data on acetazolamide compared with spironolactone showed a reduction of the risk of AMS with the administration of acetazolamide (RR 0.36; 95% CI = 0.18 to 0.70; 232 participants; low quality of evidence). No events of HAPE or HACE were reported. Adverse events were not evaluated. </p> <p>In addition, we did not find any studies comparing endothelin‐1 antagonists (such as bosentan) with a placebo. We also did not find evidence of benefits and harms of anticonvulsant drugs (such as phenytoin), in terms of primary and secondary outcomes selected for our review. </p> </section> </section> <section id="CD012983-sec-0102"> <h3 class="title" id="CD012983-sec-0102">Overall completeness and applicability of evidence</h3> <p>We identified a limited number of studies addressing the effectiveness and safety of the less common pharmacological interventions for the prevention of HAI, with almost all the evidence being specifically about AMS. We included eight studies in this review (334 participants). Few of the included studies reported on our primary and secondary outcomes. The findings of this review should be interpreted carefully in the light of the methodological limitations of the included clinical trials, the lack of information on aspects related to these interventions, as well as the different criteria and scales used (see also <a href="./references#CD012983-bbs2-0131" title="Nieto EstradaVH , Molano FrancoD , MedinaRD , Gonzalez GarayAG , Martí‐CarvajalAJ , Arevalo‐RodriguezI . Interventions for preventing high altitude illness: Part 1. Commonly‐used classes of drugs. Cochrane Database of Systematic Reviews2017, Issue 6. [DOI: 10.1002/14651858.CD009761.pub2] ">Nieto 2017</a> for more information regarding scales used). It also highlights the lack of reports of adverse events. </p> </section> <section id="CD012983-sec-0103"> <h3 class="title" id="CD012983-sec-0103">Quality of the evidence</h3> <p>We used the GRADE system to assess the quality of the body of evidence associated with primary and secondary outcomes. (See <a href="./full#CD012983-tbl-0001">summary of findings Table for the main comparison</a>, <a href="./full#CD012983-tbl-0002">summary of findings Table 2</a>, <a href="./full#CD012983-tbl-0003">summary of findings Table 3</a> and <a href="./full#CD012983-tbl-0004">summary of findings Table 4</a> for complete assessments and the rationale for ratings.) Risk of bias and imprecision were the GRADE considerations most affected in the assessment of the quality of the evidence in our review, especially for risk of AMS in all comparisons (downgraded two levels in most of the cases). Inconsistency was only detected for the risk of AMS in spironolactone versus placebo (downgraded three levels). Indirectness and publication bias were not detected for the gathered evidence. </p> </section> <section id="CD012983-sec-0104"> <h3 class="title" id="CD012983-sec-0104">Potential biases in the review process</h3> <p>In all cases, we followed the methodology for systematic reviews outlined in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD012983-bbs2-0104" title="HigginsJP , GreenS , editor(s) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011</a>). However, we had to make extensive modifications to the published protocol (<a href="./references#CD012983-bbs2-0159" title="Martí‐Carvajal ArturoJ , HidalgoR , Simancas‐RacinesD . Interventions for preventing high altitude illness. Cochrane Database of Systematic Reviews2012, Issue 4. [DOI: 10.1002/14651858.CD009761] ">Martí‐Carvajal 2012</a>), due to the need to update the methods to the current Methodological Expectations of Cochrane Intervention Reviews (MECIR) (<a href="./references#CD012983-bbs2-0105" title="Higgins JPT, Lasserson T, Chandler J, Tovey D, Churchill R. Methodological Expectations of Cochrane Intervention Reviews. Cochrane: London, Version 1.05, 2016. ">Higgins 2016</a>). For instance, the MECIR guidelines were published after publication of this review's protocol (<a href="./references#CD012983-bbs2-0159" title="Martí‐Carvajal ArturoJ , HidalgoR , Simancas‐RacinesD . Interventions for preventing high altitude illness. Cochrane Database of Systematic Reviews2012, Issue 4. [DOI: 10.1002/14651858.CD009761] ">Martí‐Carvajal 2012</a>), and some sections required major post‐hoc modifications. At that point we had some knowledge about the results of our search, and this could have introduced bias in these modifications. All modifications were approved by the Cochrane Anaesthesia, Critical and Emergency Care Group (ACE) editors in collaboration with clinical and statistical experts, and we believe the risk of bias was reduced as far as possible. In addition, one major change was the decision to split the review into three parts, considering the numerous interventions assessed for HAI prevention. This decision was guided by the search results submitted in a first draft of the review, and because the ACE editors considered that the readability of the information could be adversely affected without this division. We believe the subgroups help understanding of the heterogeneity and variability of interventions in this field, as well as allow the presentation of critical information in a clearer manner. We also suggest all these interventions should be analysed in a network meta‐analysis, in order to determine which interventions are more effective in avoiding the onset of new cases of this condition. Please see <a href="#CD012983-sec-0140">Differences between protocol and review</a> for the full list of the modifications undertaken for this series of reviews about the prevention of HAI. </p> <p>Twelve potentially eligible studies did not provide enough information to enable us to classify them as included or excluded. This was because they were published only as conference proceedings, or because we did not have access to the full texts when we were completing this review. We also considered 12 additional studies as ongoing because they were published only as protocols. </p> <p>An additional potential bias in our review was the difficulty we had in contacting trial authors to request additional information. We were unable to undertake this task due to, in most cases, no clear contact information being supplied in the publication. In addition, at least half of the included studies were published more than two decades ago. Trial authors might have been a potential source of information to document the rate of adverse events related to assessed interventions. We found that most of the studies (more than 87%) did not report adverse events associated with the classes of drugs commonly used for the prevention of AMS. This constitutes a lack of information about the safety profile of the drugs in question. </p> <p>In addition, we did not expect to encounter any unit of analysis issues as we did not expect to find cross‐over studies. However, we identified in this review one cross‐over study (12 cross‐over in total for this series of reviews) in our search strategies. In order to avoid bias in the development of our review, we analysed those studies separately. </p> </section> <section id="CD012983-sec-0105"> <h3 class="title" id="CD012983-sec-0105">Agreements and disagreements with other studies or reviews</h3> <p>Most of the published reviews recommend slow ascent, and acetazolamide or dexamethasone as alternatives for the prevention of this condition (<a href="./references#CD012983-bbs2-0090" title="FlahertyGT , KennedyKM . Preparing patients for travel to high altitude: advice on travel health and chemoprophylaxis. British Journal of General Practice : the Journal of the Royal College of General Practitioners2016;66(642):e62‐4. [PUBMED: 26719484] ">Flaherty 2016</a>; <a href="./references#CD012983-bbs2-0111" title="KayserB , DumontL , LysakowskiC , CombescureC , HallerG , TramerMR . Reappraisal of acetazolamide for the prevention of acute mountain sickness: a systematic review and meta‐analysis. High Altitude Medicine &amp; Biology2012;13(2):82‐92. [PUBMED: 22724610] ">Kayser 2012</a>; <a href="./references#CD012983-bbs2-0112" title="KhodaeeM , GrotheHL , SeyfertJH , VanBaakK . Athletes at high altitude. Sports Health2016;8(2):126‐32. [PUBMED: 26863894] ">Khodaee 2016</a>; <a href="./references#CD012983-bbs2-0115" title="LowEV , AveryAJ , GuptaV , SchedlbauerA , GrocottMP . Identifying the lowest effective dose of acetazolamide for the prophylaxis of acute mountain sickness: systematic review and meta‐analysis. BMJ (Clinical research ed.)2012;345:e6779. [PUBMED: 23081689] ">Low 2012</a>; <a href="./references#CD012983-bbs2-0137" title="RitchieND , BaggottAV , Andrew ToddWT . Acetazolamide for the prevention of acute mountain sickness‐‐a systematic review and meta‐analysis. Journal of Travel Medicine2012;19(5):298‐307. [PUBMED: 22943270] ">Ritchie 2012</a>; <a href="./references#CD012983-bbs2-0144" title="SeupaulRA , WelchJL , MalkaST , EmmettTW . Pharmacologic prophylaxis for acute mountain sickness: a systematic shortcut review. Annals of Emergency Medicine2012;59(4):307‐317.e1. [PUBMED: 22153998] ">Seupaul 2012</a>; <a href="./references#CD012983-bbs2-0158" title="ZafrenK . Prevention of high altitude illness. Travel Medicine and Infectious Disease2014;12(1):29‐39. [PUBMED: 24393671] ">Zafren 2014</a>). </p> <p><a href="./references#CD012983-bbs2-0081" title="Committee to Advise on Tropical Medicine and Travel (CATMAT). Statement on high‐altitude illnesses. An Advisory Committee Statement (ACS). Canada Communicable Disease Report = Relevé des maladies transmissibles au Canada2007;33(ACS‐5):1‐20. [PUBMED: 17520777] ">CATMAT 2007</a> proposed a role for spironolactone (25 mg orally four times a day) in prevention of HAI, but accepted this recommendation needed confirmation with further evidence. Likewise, Marmura and colleagues showed that gabapentin and sumatriptan could have a clearer role in treatment of HAI instead of prevention (<a href="./references#CD012983-bbs2-0124" title="MarmuraMJ , HernandezPB . High‐altitude headache. Current Pain and Headache Reports2015;19(5):483. [PUBMED: 25795155] ">Marmura 2015</a>). We did not find any reviews about other options such as bosentan, phenytoin or magnesium, and these pharmacological interventions are not recommended in current clinical practice guidelines for the prevention of this condition. </p> <p>Recently, Davis and colleagues discussed current advances in the prevention and treatment of HAI (<a href="./references#CD012983-bbs2-0085" title="DavisC , HackettP . Advances in the Prevention and Treatment of High Altitude Illness. Emergency Medicine Clinics of North America2017;35(2):241‐60. [PUBMED: 28411926] ">Davis 2017</a>). The authors stated that prophylaxis of HAI has as a main goal optimal acclimatization to prevent these conditions, so pharmacological interventions such as acetazolamide remain as the major strategy in AMS and HAPE prevention. In addition, nifedipine and phosphodiesterase inhibitors are also proposed as useful agents in prevention of HAPE. However, none of the drugs included in this review is proposed as having a role in the prevention of HAI conditions (<a href="./references#CD012983-bbs2-0085" title="DavisC , HackettP . Advances in the Prevention and Treatment of High Altitude Illness. Emergency Medicine Clinics of North America2017;35(2):241‐60. [PUBMED: 28411926] ">Davis 2017</a>). Likewise, Luks and colleagues stated that pharmacological interventions can be considered for individuals at high risk of developing HAI conditions (<a href="./references#CD012983-bbs2-0120" title="LuksAM , SwensonER , BartschP . Acute high‐altitude sickness. European Respiratory Review : an Official Journal of the European Respiratory Society2017;26(143):160096. [PUBMED: 28143879] ">Luks 2017</a>). Acetazolamide and dexamethasone have been considered valid alternatives in prevention of AMS; and nifedipine, tadalafil and salmeterol are options considered for HAPE prevention in individuals with a history of this condition (<a href="./references#CD012983-bbs2-0120" title="LuksAM , SwensonER , BartschP . Acute high‐altitude sickness. European Respiratory Review : an Official Journal of the European Respiratory Society2017;26(143):160096. [PUBMED: 28143879] ">Luks 2017</a>). </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD012983-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012983/media/CDSR/CD012983/urn:x-wiley:14651858:media:CD012983:CD012983-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012983/media/CDSR/CD012983/image_t/tCD012983-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram." data-id="CD012983-fig-0001" src="/cdsr/doi/10.1002/14651858.CD012983/media/CDSR/CD012983/image_n/nCD012983-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012983/full#CD012983-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012983/media/CDSR/CD012983/image_n/nCD012983-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012983-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012983/media/CDSR/CD012983/urn:x-wiley:14651858:media:CD012983:CD012983-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012983/media/CDSR/CD012983/image_t/tCD012983-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD012983-fig-0002" src="/cdsr/doi/10.1002/14651858.CD012983/media/CDSR/CD012983/image_n/nCD012983-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012983/full#CD012983-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012983/media/CDSR/CD012983/image_n/nCD012983-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012983-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012983/media/CDSR/CD012983/urn:x-wiley:14651858:media:CD012983:CD012983-AFig-FIG03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012983/media/CDSR/CD012983/image_t/tCD012983-AFig-FIG03.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD012983-fig-0003" src="/cdsr/doi/10.1002/14651858.CD012983/media/CDSR/CD012983/image_n/nCD012983-AFig-FIG03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012983/full#CD012983-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012983/media/CDSR/CD012983/image_n/nCD012983-AFig-FIG03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012983-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012983/media/CDSR/CD012983/urn:x-wiley:14651858:media:CD012983:CD012983-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012983/media/CDSR/CD012983/image_t/tCD012983-CMP-001-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Spironolactone: spironolactone vs. placebo, Outcome 1 Risk of acute mountain sickness." data-id="CD012983-fig-0004" src="/cdsr/doi/10.1002/14651858.CD012983/media/CDSR/CD012983/image_n/nCD012983-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 Spironolactone: spironolactone vs. placebo, Outcome 1 Risk of acute mountain sickness. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012983/references#CD012983-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012983/media/CDSR/CD012983/image_n/nCD012983-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD012983-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Sumatriptan compared with placebo for preventing high altitude illness</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Sumatriptan compared with placebo for preventing high altitude illness</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> participants at risk of high altitude illness<br/> <b>Setting:</b> High altitude (Ecuador) </p> <p><b>Intervention:</b> sumatriptan<br/> <b>Comparison:</b> placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Placebo</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Sumatriptan</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Risk of acute mountain sickness</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>412 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>177 per 1000</b><br/> (91 to 346) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.43</b> <br/> (0.21 to 0.84) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>102<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low</b><sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Risk of high altitude pulmonary oedema</b> ‐ not reported </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>Not estimable</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Risk of high altitude cerebral oedema</b> ‐ not reported </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>Not estimable</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Risk of adverse events</b> ‐ not reported </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>Not estimable</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Downgraded 2 levels due to imprecision. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Sumatriptan compared with placebo for preventing high altitude illness</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012983/full#CD012983-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD012983-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Magnesium citrate compared with placebo for preventing high altitude illness</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Magnesium citrate compared with placebo for preventing high altitude illness</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> participants at risk of high altitude illness<br/> <b>Setting:</b> High altitude (Italy) </p> <p><b>Intervention:</b> magnesium citrate<br/> <b>Comparison:</b> placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>placebo</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Magnesium</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Risk of acute mountain sickness</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>314 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>343 per 1000</b><br/> (176 to 669) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.09</b> <br/> (0.55 to 2.13) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>70<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low</b><sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Risk of high altitude pulmonary oedema</b>‐ not reported </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>Not estimable</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Risk of high altitude cerebral oedema</b>‐ not reported </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>Not estimable</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Risk of adverse events: Loose stools</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>114 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>371 per 1000</b><br/> (134 to 1000) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 3.25</b> <br/> (1.17 to 8.99) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>70<br/> (1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊝⊝<br/> <b>Low</b><sup>1</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Imprecision downgraded by 2 levels due to insufficient sample size to determine whether there are differences or no differences between these 2 groups. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Magnesium citrate compared with placebo for preventing high altitude illness</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012983/full#CD012983-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD012983-tbl-0003"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Spironolactone compared with placebo for preventing high altitude illness</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Spironolactone compared with placebo for preventing high altitude illness</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> participants at risk of high altitude illness<br/> <b>Setting:</b> High altitude (Tanzania) </p> <p><b>Intervention:</b> spironolactone<br/> <b>Comparison:</b> placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Placebo</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Spironolactone</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Risk of acute mountain sickness</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>205<br/> (2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low</b><sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR ranged from 0.40 to 1.44</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Risk of high altitude pulmonary oedema</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>Not estimable</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>193<br/> (1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No HAPE events recorded</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Risk of</b> High altitude<b>cerebral oedema</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>Not estimable</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>193<br/> (1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No HACE events recorded</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Risk of adverse events</b> ‐ not reported </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>Not estimable</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Quality of evidence downgraded from high to very low due to a high risk of bias, imprecision and inconsistency. </p> <p>2 Quality of evidence downgraded from high to low due to unclear risk of selection, performance and detection bias, as well as imprecision issues </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Spironolactone compared with placebo for preventing high altitude illness</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012983/full#CD012983-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD012983-tbl-0004"> <div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Acetazolamide compared with spironolactone for preventing high altitude illness</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Acetazolamide compared with spironolactone for preventing high altitude illness</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population</b> : participants at risk of high altitude illness<br/> <b>Setting</b>: High altitude (Nepal) </p> <p><b>Intervention</b> : spironolactone<br/> <b>Comparison</b>: placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Spironolactone</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Acetazolamide</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Risk of acute mountain sickness</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>237 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>85 per 1000</b><br/> (43 to 168) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.36</b> <br/> (0.18 to 0.70) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>232<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Risk of high altitude pulmonary oedema</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>232<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No HAPE events recorded</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Risk of high altitude cerebral oedema</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>232<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No HACE events recorded</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Risk of adverse events</b> ‐ not reported </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio; </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Risk of bias downgraded by 1 level due to unclear selection, performance and detection bias.<br/> <sup>2</sup> Imprecision downgraded by 1 level due to insufficient sample size to determine whether there are differences or no between these 2 groups. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Acetazolamide compared with spironolactone for preventing high altitude illness</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012983/full#CD012983-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012983-tbl-0005"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Spironolactone: spironolactone vs. placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Risk of acute mountain sickness <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Spironolactone: spironolactone vs. placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012983/references#CD012983-tbl-0005">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD012983&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD012983-note-0003">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD012983-note-0011">فارسی</a> </li> <li class="section-language"> <a class="" href="ms#CD012983-note-0002">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="zh_HANT#CD012983-note-0001">繁體中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734064000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734064000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772746000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012983\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012983\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012983\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD012983"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012983\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012983\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012983\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012983\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012983\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD012983"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012983\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012983\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012983\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD012983"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012983\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012983\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012983\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD012983"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=PrHmaMrX&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD012983&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD012983';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD012983/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD012983/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD012983%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740725559779"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD012983/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"/> <span class="taglib-text hide-accessible">Sign In</span> </span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740725559783"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD012983/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918e7e35bc75f466',t:'MTc0MDcyNTU2MC4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 